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ABSTRACT:  
Endothelial cells form the inner lining of blood vessels and regulate key blood 
vessel functions including host defense reactions, vascular smooth muscle tone, 
angiogenesis, and tissue fluid homeostasis. The occurrence of a pathological 
condition can lead to inflammation, a protective and tightly regulated response 
involving host cells, blood vessels and proteins. This process is promoted by 
circulating cytokines and other chemical mediators such as tumor necrosis factor-
alpha (TNF-α), interleukins, thrombin, a few examples. Inflammation can be acute 
or chronic in nature and is characterized by specific cell receptor expression 
patterns on the endothelial layer and an increase in endothelial cell-cell gaps. 
Upregulation of intercellular adhesion molecule-1 (ICAM-1) on endothelial surface 
occurs during inflammation, and ICAM-1 plays an important role in leukocyte 
adhesion and recruitment. Understanding the dynamic nature of receptor 
expression and endothelial cell gap formation during inflammation would provide 
fundamental physiological information and is also essential for evaluating drug and 
other biomolecules targeted binding and uptake by endothelial cells. 
The far reaching accessibility combined with heterogenic behaviour make 
microvascular endothelium an attractive target for targeted drug delivery. Dynamic 
and complex processes governing the targeted drug particle binding and 
distribution on blood microvasculature are still partially understood. Part of this 
work focuses on the characterization of particle delivery in microcirculation on an 
ICAM-1 coating based blood vessel mimicking microfluidic device. In 
microvasculature the vessel size is comparable to that of red blood cells (RBCs) 
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and the existence of blood cells largely influences the dispersion and binding 
distribution of drug loaded particles. Various factors that influence particle 
distribution and delivery such as the vessel geometry, shear rate, blood cells, 
particle size, particle antibody density were considered in this study.  
Better understanding of the pathologically challenged local endothelial cell layer 
microenvironment can help us engineer drug carriers decorated with specific 
biomolecules which can improve the pharmacokinetics and pharmacodynamics of 
drugs. In this study we also developed a biomimetic blood vessel model by 
culturing confluent, flow aligned, Endothelial cells in a microfluidic platform, 
capable of being treated with inflammatory mediators locally. Primary bovine aortic 
endothelial cells (BAOECs) were grown on semi-permeable membrane with pores 
that separates an upper and lower channel made of polydimethylsiloxane (PDMS). 
This dual channel design allowed localized direct TNF-α treatment on the 
endothelial cell layer leading to expression of surface ICAM-1. This model 
simulated spatially controlled healthy and pathologically challenged endothelial 
cells in the same channel and thus has the ability to investigate the 
microenvironment of locally activated endothelial cells. We characterized 
endothelial cell culture in this platform and and performed real-time in situ 
characterization of localized pro-inflammatory endothelial activation. Anti-ICAM-1 
coated particles (210 nm and 1 µm diameter) of different antibody coating densities 
were used as imaging probes and availability of ICAM-1 was probed. This allowed 
the investigation of spatial resolution and accessibility of ICAM-1 molecules on 
endothelial cells for targeted binding studies. Anti-ICAM-1 coated particles 
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specifically bound to TNF-α activated BAOECs in an antibody coating density, FSS 
and particle size dependent manner. F-actin remodelling was also observed in 
TNF-α treated and downstream sections of the channel. This work has developed 
a more realistic in vitro vascular model that can independently integrate various 
factors to effectively mimic a complex physiological endothelial cell 
microenvironment and has been applied to study endothelial cell 
microenvironment under localized inflammatory triggering.  
Inflammatory responses in endothelial cells are characterized by an increase in 
vascular permeability by formation of intercellular gaps. The biomimetic blood 
vessel model developed by culturing confluent, flow aligned, and endothelial cells 
in a microfluidic platform (described prior) was utilized in characterizing the 
dynamic nature of vascular permeability under inflammation. BAOECs were 
subjected to in vivo levels of prolonged flow and then treated with thrombin, a 
serine protease. Thrombin induced profound increase of endothelial cell 
monolayer permeability in a rapid and reversible way. Endothelial cells cultured in 
the upper channel were exposed to media mixed with thrombin and a tracer 
molecule. Tracer molecule samples were collected real time and analysed using 
spectroscopy, and the dynamic nature of the process was studied. The remodelling 
of F-actin in BAOECs after thrombin treatment was also characterized for different 
time points. Better understanding of the dynamics involved in increased vascular 
permeability can help engineer strategies to enhance targeted drug delivery 
through these para-cellular gaps.  
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Chapter 1 
Introduction 
Endothelial cells form the inner lining or 'tunica intima' of blood vessels and are 
exposed to dynamically varying factors like hemodynamic conditions (shear stress, 
laminar, turbulent flow), biochemical signals (cytokines) and interaction with other 
cell types (smooth muscle cells, monocytes, platelets etc). Blood vessel functions 
are regulated by an interaction between these factors. They form an interface 
between circulating blood in the lumen and the tissue layer beyond the vessel wall. 
Thus they form a barrier, and a potential target for localized, enhanced and 
effective targeted drug delivery. Endothelial cells express specific cell-surface 
molecules under various pathological conditions, which are absent or barely 
present on healthy and normal blood vessels [1]. Targeting these epitopes on the 
endothelial cell surface by coupling these potential endothelial cell surface markers 
with carefully engineered drug carriers (considering features such as valence and 
surface density of ligands, the carrier geometry and encapsulation into protective 
polymeric carriers) effective and active vascular-targeted drug delivery systems 
can be achieved. These systems will be capable of avoiding toxicity based drug 
side effects and thus acceptable in a clinical domain. 
Delivery systems in the form of liposomes, dendrimers, micelles and polymers, as 
well as the more conventional and inorganic carbon, silica, iron and gold based 
platforms are widely used as drug carriers [2-5]. The size of the carrier plays a 
pivotal role in ligand-receptor based molecular recognition and binding to cell 
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surface (a larger particle would be less efficient in targeting receptors closer to cell 
plasmalemma). The uptake efficacy of nanoparticle (NP) based drug carriers is 
higher compared to their larger micron scale counterparts, which are easily cleared 
off by the human mononuclear phagocyte system [6]. Pathological studies of 
conditions like inflammation, atherosclerosis and cancer have observed 
accumulation of NP based drug therapies based on increased permeability of 
blood vessels in the disease region [7-11]. Various techniques in targeted drug 
delivery have been developed in recent years  to reduce side effects, toxicity, and 
drug dosage [12]. Dynamic and complex processes governing the targeted drug 
particle binding and distribution on endothelial cell surface are still only partially 
understood.  
Targeted binding of drug carriers should occur specifically on endothelial cells of 
blood vessels in the pathologically challenged region for maximum efficacy and to 
prevent drug toxicity related side-effects. The complex inflammatory cellular 
mechanisms contributing to upregulation of adhesion molecules on endothelial cell 
surface that can act as drug targetshave proved elusive. A better understanding of 
the dynamic nature of the pathological process and the contribution of various 
heterogeneous factors towards the cellular mechanisms governing these 
processes would help us develop therapeutic strategies that can have enhanced 
impact.  
Scientists have employed in vivo and in vitro platforms to shed more light on blood 
vessel physiology. In vivo studies often require complex mammalian models and 
time-consuming surgical protocols, making them expensive and challenging 
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platforms. They also raise ethical issues and such models also respond differently 
than to humans as interspecies predictability is low in response to drugs and 
diseases [13]. In vivo studies also allow only limited control of the heterogeneous 
physical, chemical, and biological parameters influencing the blood vessel and 
present challenges with respect to imaging as well [14]. Relatively easier and 
simple in vitro platforms are also under use, but endothelial cells tend to loose their 
native phenotype in these conditions. This demands an alternative, practical, 
human-centered and bio-mimetic blood vessel mimicking platform that can provide 
culture conditions for endothelial cells that are comparable to the 3D native in vivo 
endothelium. This might also help sustain the endothelial cell phenotype closer to 
its native state while being cultured in vitro. Such a platform should maintain the 
quiescent phenotype of endothelial cells under normal conditions by down-
regulating the pro-inflammatory and proliferative pathways of vascular endothelial 
cells. A  blood vessel model can achieve this by subjecting the endothelial cells to 
native in vivo conditions, like constantly renewing essential biomolecule supply, 
flow conditions, constant removal of waste and undesirable molecules, etc. [15-
16]. Such a biomimetic model can simulate disease related inflammatory 
conditions when triggered in a close to in vivo manner, and we can apply such a 
system to study the dynamics of endothelial cell microenvironments.  
The two main objectives of this work are, 1) understand the optimal drug carrier 
properties for targeted delivery in specific microvascular geometries and 
hemodynamic conditions for drug carrier transport and binding on endothelial cells 
in the blood stream; and 2) study the dynamic and heterogeneous nature of 
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receptor upregulation and intercellular gap formation in a blood vessel 
microenvironment under inflammatory conditions. 
These objectives have been accomplished through the completion of the following 
aims: 
Aim 1: Develop a microfluidic blood vessel model mimicking a microvasculature 
blood vessel environment in an inflammatory state by specific cell receptor protein 
coating. 
Aim 2: Apply this platform towards characterizing targeted particle binding and 
distribution, considering various factors like blood vessel geometry, flow shear 
rate, effect of blood cell flow and drug carrier features like size, shape and ligand 
coating (affinity and coating density).  
The receptor-targeted delivery system designed to quantitatively assess 
multivalent nanoparticle adhesion under physiological shear flow conditions allows 
optimization of carrier adhesion for maximizing the binding efficiency. ICAM-1 has 
been directly associated with pathological conditions like atherosclerosis, 
autoimmune disorder, transplant rejection, and cancer. We apply ICAM-1 protein 
coating on a microfluidic platform at a density expressed in vivo by pathologically 
challenged endothelium. Polystyrene particles of 210 nm and 2 µm diameter 
coated with monoclonal antibody specific for ICAM-1 are used as model delivery 
carriers. This study provides a mechanical understanding of drug carrier transport 
and binding in microvessels. The tool also defines parameters for optimal drug 
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dosage and targeting in specific vascular geometries and hemodynamic 
conditions.  
Aim 3: Engineer an alternative, human-centered, bio-mimetic blood vessel 
mimicking platform by growing endothelial cells in culture conditions close to their 
native in vivo environment. This platform can mimic localized disease conditions 
by spatially controlled pro-inflammatory stimulation of endothelial cells.  
Aim 4: Apply this platform to investigate the microenvironment of locally activated 
endothelial cells by studying the dynamic nature of cell receptor upregulation and 
increase in vessel permeability under inflammation.   
This model integrates a confluent, flow aligned cell layer in a microfluidic platform 
and is designed to allow the culture of endothelial cells expressing quiescent and 
inflammatory response in the same channel. This investigation of endothelial cell 
microenvironment during both these states in the same channel brings to light the 
nature of transition between the two states. We studied the localized dynamics of 
ICAM-1 protein expression on the surface of endothelial cells using imaging probes 
and their related cytoskeletal remodelling under inflammation in this work. By 
tuning the design and assay protocol it was also possible to use the same 
microfluidic blood vessel model to study the increase in blood vessel permeability 
under inflammation. Endothelial cells were treated with thrombin, an acute 
inflammatory mediator and the increase in vessel permeability was characterised 
by studying diffusion of tracer molecules. Applying this biomimetic platform 
towards targeted nanodrug delivery and trans-endothelial migration studies allows 
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the understanding on cellular level chemistry and mechanics involved in drug 
carrier binding and uptake by endothelial cells. 
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Chapter 2 
Background and Significance 
Blood vessels extend throughout the body and mediate gas exchange, nutrient 
and waste transport, and immune defense [15]. An endothelial cell monolayer 
forms the inner layer and is in constant contact with blood flow. This cell layer 
contributes a basement membrane composed of fibronectin, collagen IV, laminins, 
and heparan sulfate proteoglycans, which directly or indirectly influences diverse 
blood vessel processes such as cell differentiation, attachment, migration, 
polarization, guidance, and survival [16]. Vascular smooth muscle cells or 
pericytes cover the endothelial cells and form the middle layer, dependening on 
the blood vessel size and position. Arteries are supported by smooth muscle cells 
thereby regulating the vessel tone, whereas capillaries are sparsely supported by 
specialized mesenchymal cells denoted as pericytes. The fibroblasts and matrix 
form the outer layer of the blood vessels. The different layers of a blood vessel are 
detailed in Figure 1 along with their functions. 
The endothelial cell layer or tunica intima of the blood vessel forms an interface 
between circulating blood in the lumen and the tissue layer beyond the vessel wall. 
This layer regulates multiple functions including host defense reactions, vascular 
smooth muscle tone, angiogenesis, and tissue fluid homeostasis. The endothelial 
cell layer does play a part  in regulating these processes by secreting specific cell 
signalling factors. For example, urokinase and tissue-type plasminogen activators 
are secreted by endothelial cell to dissolve blood clots through the generation of 
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the fibrin-degrading protease and plasmin. Similarly blood vessel tone is controlled 
by nitric oxide, prostacyclin, and additional factors, and endothelial factors are also 
able to suppress platelet aggregation as antithrombotic factors. A failure by the 
blood vessel endothelial cells to perform their physiologic functions is referred to 
as endothelial dysfunction or endothelial activation. This is often a maladaptive 
response to a pathological stimuli. Endothelial cells secrete a variety of agents 
including cytokines, reactive oxygen species, growth factors, and a variety of 
chemoattractants during thrombosis or other pathological conditions that are 
associated with the inflammation process. Endothelial dysfunction is characterized 
by upregulated expression of cellular adhesion molecules, compromised barrier 
integrity (leading to increased leukocyte recruiting), increased vascular smooth 
muscle tone [secondary to impaired processing of vasodilators (nitric oxide and 
prostacyclin) as well as increased production of vasoconstrictors including 
endothelin], and reduced resistance to thrombosis as phenotypic features [17-19].    
In developed countries cardiovascular diseases form the primary reason for 
mortality and morbidity. A report in 2012 by the American Heart Association found 
that in 2008 an average of one death occurred every 39 seconds due to 
cardiovascular diseases, accounting to more than 2200 American deaths each day 
Annual report by the American Cancer Society  estimated 1,658,370 new cancer 
cases diagnosed and 589,430 cancer deaths in the US during the year of 2015 
[20]. Pathogenesis of a broad spectrum of human diseases is marked by 
alterations of endothelial cells and the vasculature. The endothelium is directly 
involved in stroke, diabetes, insulin resistance, chronic kidney failure, tumor 
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growth, metastasis, venous thrombosis, and severe viral infectious diseases, 
along with cardiovascular diseases (restenosis, atherosclerosis, hypertension, 
ischemia), neurological disorders (stroke, Alzheimer's disease) and other systemic 
inflammatory diseases (rheumatoid arthritis, inflammatory bowel diseases, lupus, 
psoriasis, spondyloarthritis) [17, 21-26]. Therefore the dysfunction of the vascular 
endothelium can be considered a mark of human diseases.  
 
Blood vessels are an intricate network and have accessibility throughout the body. 
The human vascular system possesses unique physiological features that can be 
exploited for enhanced and effective targeted drug delivery. Many human vascular 
diseases are exquisitely restricted to specific types of vessels. For example, the 
part played by platelets in the initiation of arterial and venous thrombosis differs, 
TUNICA 
ADVENTITIA 
(outermost layer) 
TUNICA MEDIA 
(middle layer) 
TUNICA INTIMA 
(innermost layer) 
Mainly composed of smooth muscle cells and pericytes 
Exhibit cardioprotective functions (promotion of 
angiogenesis, reduction of scar formation and inhibition of 
chronic inflammation) 
Mainly composed of collagen, fibroblast and the endothelial 
cellM matrix 
Plays an active role in cell trafficking, immune response 
mediation and vascular remodeling 
Mainly composed of endothelial cells 
Provides structural integrity for blood vessels by forming 
semi-permeable membrane and thromboresistant wall 
Controls blood flow and vessel tone; platelet activation, 
adhesion and aggregation; leukocyte adhesion, cell 
signaling cascades 
Figure 1: Layers of the blood vessel. Outer tunica adventitia, middle tunica media, 
and inner tunica intima, their corresponding cell composition and functions. 
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as does the level of risk these two types of blood vessels are exposed to in 
atherosclerosis. It is also common for vasculitis to show preference for specific 
arteries, veins, or capillaries or for certain organs. Tumor cells may show similar 
predilection in metastasizing via specific vascular beds [27]. The thin layer of 
endothelial cell lining the interior surface of blood vessels has the accessibility and 
uniqueness to be  a potential target for localized, enhanced and effective targeted 
drug delivery. endothelial cells express specific cell-surface molecules under 
various pathological conditions, which are absent or barely present on healthy and 
normal blood vessels [1]. By coupling potential endothelial cell surface markers 
with carefully engineered drug carriers (considering features such as valence and 
surface density of ligands, the carrier geometry and encapsulation into protective 
polymeric carriers), effective and active vascular-targeted drug delivery systems 
can be achieved, avoiding side effects and acceptable in a clinical domain [28]. 
The vascular networks in healthy and disease state also differ in their 
morphological characteristics other than the molecular receptors expressed. The 
pathology of several inflammation related conditions (atherosclerosis, ischemia 
reperfusion injury, stroke, hypertension and also thrombosis, diabetes, acute lung 
injury, and sepsis, etc.) are characterized by endothelial cell layers with 
intercellular gaps that form pores, making them leaky. Physiological and 
pathological conditions of inflammatory diseases bring about this increased 
permeability in vasculature [19]. The same mechanism has been found to enhance 
drug carrier delivery to vascularized solid tumors via a phenomena termed 
enhanced permeation and retention effect [29-30]. The increase in permeability of 
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the vascular network in pathologically challenged regions can be used to 
potentially increase the delivery of therapeutic agents to the site of infection. This 
change in morphological characteristics of the endothelium can be combined with 
the marked increase in expression of specific cell receptors to facilitate enhanced 
targeted drug delivery.  
Strict regulations are in effect for drug development and testing. Conventional 
animal experimental models to evaluate drug delivery systems raise ethical issues 
and such models also respond different than humans as interspecies predictability 
is low in response to drugs and diseases [13]. In vivo studies also allow only limited 
control of the heterogeneous physical, chemical, and biological parameters 
influencing the blood vessel and present challenges with respect to imaging as 
well [14]. This demands a practical, human-centered and bio-mimetic alternative 
testing platform, which can provide pharmaceutical research greater security and 
shorten the path to new drugs and delivery systems. By applying the principles of 
engineering and biology, novel in vitro biological substitutes to test drug delivery 
systems can be developed. Creating a bio-hybrid artificial blood vessel by 
incorporating tissue specific endothelial cells and studying endothelial cell 
microenvironment for specific disease foci holds huge potential.  
2.1 Blood vessel; its structure and function  
Blood vessels are intricate networks of hollow tubes that transport blood 
throughout the entire body. This is an essential function as blood delivers valuable 
nutrients and removes wastes from our cells. Blood vessels are constructed of 
layers of connective tissue and muscle. The inner blood vessel layer is formed of 
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endothelium. In capillaries and sinusoids, the endothelium comprises the majority 
of the vessel. Blood vessel endothelium is continuous with the inner tissue lining 
of organs such as the brain, lungs, skin, and heart.  
2.1.1 Types of Blood Vessels 
Arteries 
Arteries are elastic vessels that transport blood away from the heart. Pulmonary 
arteries carry blood from the heart to the lungs where oxygen is picked up by red 
blood cells. Systemic arteries deliver blood to the rest of the body.  
Veins 
Veins are elastic vessels that transport blood to the heart. Veins can be 
categorized into four main types: pulmonary, systemic, superficial, and deep veins.  
Capillaries 
Capillaries are extremely small vessels located within the tissues of the body that 
transport blood from the arteries to the veins. Fluid exchange between capillaries 
and body tissues takes place at capillary beds.  
Sinusoids 
Sinusoids are extremely small vessels located within the liver, spleen, and bone 
marrow. 
Blood is circulated through the body via the cardiovascular system. This system is 
comprised of the heart and the circulatory system. Blood vessels carry blood from 
the heart to all areas of the body. The blood travels from the heart via arteries to 
smaller arterioles, then to capillaries or sinusoids, then to venules, to veins, and 
back to the heart. Microcirculation deals with the flow of blood from arterioles to 
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capillaries or sinusoids to venules. As blood moves through the capillaries, 
substances such as oxygen, carbon dioxide, nutrients, and wastes are exchanged 
between the blood and the fluid that surrounds cells. Regions of blood vessel with 
the microcirculation play a critical role in targeted drug delivery as these regions 
have accessibility all throughout the body facilitating transport for drug carriers to 
site of delivery.    
The endothelial cell layer exhibits both morphological and molecular heterogeneity 
among and within tissues. Capillary endothelium expresses variation in 
arrangement for different vascular sites and it is recognized based on differences 
in function. The capillary endothelium in brain and retina is lined by continuous 
endothelial cells connected by tight junctions. This helps to maintain the blood-
brain barrier, an essential physiological feature. The liver, spleen, and bone 
marrow sinusoids have a discontinuous endothelial cell lining that allows cellular 
trafficking between intercellular gaps. Meanwhile, fenestrated endothelial cells are 
present in intestinal villi, endocrine glands, and kidneys to allow selective 
permeability essential for efficient absorption, secretion, and filtering [31]. The 
phenotype and protein expression on endothelial cells from diverse tissues are 
also heterogeneous. For example, von Willebrand factor (a common endothelial 
cell marker) is not uniformly expressed on all types of vessels [32]. Also, only 3% 
of vascular endothelial cells express tissue type plasminogen activator in vivo and 
a constant and active expression of urokinase-type PA is confined only to renal 
endothelial cells [33-34]. The expression of specific cell signaling molecules after 
exposure to cytokines or endotoxin is also restricted to specific vessels 
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[35], among other examples of multiple cases of heterogeneity at the level of 
protein expression. These heterogeneities in protein expression and endothelial 
cell arrangement pattern can be utilized in designing drug delivery systems that 
are locked for specific endothelial cell location, and morphological or molecular 
expression state.     
2.2 Targeted Drug delivery 
Recently there has been a vast increase in the number of drug carrier systems 
which have been explored or already approved for use in the clinic and producing 
a significant impact on the diagnosis, treatment, and potential cure of many chronic 
diseases, including cancer, diabetes mellitus, psoriasis, Parkinson disease, 
Alzheimer disease, rheumatoid arthritis, HIV infection, infectious diseases, 
cardiovascular disorders, asthma, and drug addiction [19]. But most of the 
pharmaceutical systems do not work based on the ability of the drug agent to 
accumulate selectively and specifically in the pathological organ, tissue, or cell. 
These drug agents are distributed within the human body and non-specifically 
target the pathological situation. This leads to a situation where the drug has to 
cross various biological barriers, like other organs, cells, and intracellular 
compartments. These steps can inactivate or express undesirable and non-
specific reactions on organs and tissues that are not involved in the pathological 
process. Specific targeting of drugs to the target organ will allow higher tissue 
selectivity and local concentration. This also limits the level of drugs in non-
targeted cells and organs below toxic levels and without side effects to the host. 
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A drug carrier targeted to the vasculature should specifically bind to the intended 
endothelial cell layer expressing the specific molecules/features of pathological 
condition while withstanding the hydrodynamic forces of blood flow. Various clinical 
disorders over-express specific cell surface antigens and molecules on the 
endothelial cell layer as a response to altered physiological conditions and this can 
be exploited to achieve active vascular targeting of drug carrier systems [19]. 
Various techniques in targeted drug delivery have been developed in recent years  
to reduce side effects, toxicity, and drug dosage [12]. The use of drug carriers 
instead of drug molecules produces high affinity binding and enhanced vascular 
immuno-targeting at disease regions [36-38].  
2.3 Drug carrier properties  
Various techniques in targeted drug delivery have been developed in recent years  
to reduce side effects, toxicity, and drug dosage [12]. The use of particles as drug 
VEGF ROS Cytokine
Secreted agents 
Adhesion molecule targets CAMs, P/E-
selectin, other cell receptors 
Endothelial 
Cells 
Vessel 
Lumen 
Targeted 
Drug 
Nanocarriers 
Figure 2: Schematics of the vasculature endothelium and selected molecular 
determinants that play a pivotal role in targeted drug delivery to the endothelium. 
Surface-modified drug carriers decorated with specific antibodies, peptides, or 
small molecules were shown to accumulate in the endothelium.  
Urokines 
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carrier help in targeted delivery and release of drugs at diseased region, serving 
the dual role of diagnosis and therapy [36-37]. Specificity in targeting is introduced 
by applying ligand-receptor chemistry. Particles are coated with ligands and the 
efficacy of targeted drug delivery depends on various factors like size and shape 
of the drug carrier, its affinity and accessibility to cell surface receptor, ligand 
coating density, and multivalent or monovalent ligand configuration and its 
arrangement, among others.  
The size of the carrier plays a pivot role in ligand-receptor based molecular 
recognition and binding to cell surface (a larger particle would be less efficient in 
targeting receptors closer to cell plasmalemma). The uptake efficacy of 
nanoparticle (NP) based drug carriers is higher compared to their larger micron 
scale counterparts, which are easily cleared off by the human mononuclear 
phagocyte system [6]. This also increases the bioavailability of these drugs. NPs 
also have larger surface to volume ratio[39], which enhances their targeting 
capabilities while carrying lower drug dosages. Pathological studies of conditions 
like inflammation, atherosclerosis and cancer have observed accumulation of NP 
based drug therapies based on increased permeability of blood vessels in the 
disease region [7-11]. This phenomenon should be studied in detail to exploit the 
chance of achieving improved drug therapy success and clinical application. 
2.4 Specificity in drug carrier targeting 
Specific and nonspecific interactions can occur at the cell/particle interface when 
targeting a carrier to the endothelial cell layer. The specific interactions are 
controlled by the formation and breakage of molecular bonds among receptor 
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molecules expressed at the cell membrane and ligand molecules distributed over 
the carrier surface. Nonspecific interactions are balanced between the attractive 
and repulsive short-range forces including van der Waals, electrostatic, and steric 
forces. This becomes significant and to be considered when the particle is in close 
proximity to the vessel walls. 
A large variety of molecular determinants on the endothelial cell surface are 
available to be utilized for effective targeted drug delivery to the endothelium, as 
shown in Figure 2. Inflammation and other different clinical conditions can lead to 
diverse molecular cascade profiles by endothelial cells and this may lead to 
overexpression of different target receptors. Endothelial cell adhesion molecules 
(CAMs) are attractive candidates for targeted delivery and this family of molecules 
includes, vascular adhesion molecule-1 (VCAM-1), intracellular adhesion 
molecule-1 (ICAM-1), platelet-endothelial adhesion molecule-1 (Pendothelial 
cellAM-1) and P/E selectin. CAM molecules serve as targets for both diagnosis 
and treatment of vascular inflammatory signaling cascades [40]. Tumor cells 
produce pro-angiogenic cytokines, such as vascular endothelial growth factor, 
basic fibroblast growth factor, transforming growth factor b, and different 
interleukins which make tumor blood vessels highly proliferative [41]. This pro-
angiogenic state leads to the expression of prior mentioned surface antigens on 
the endothelial cells, which are not expressed by normal endothelium. Thus these 
antigens form good candidates for targeted vascular drug delivery. Integrin 
proteins which are over-expressed in angiogenic tumor endothelial cells and 
malignant tumor cells also are potential target endothelial cell receptors for drug 
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delivery.  
Intercellular Adhesion Molecule-1 (ICAM-1) expressed on the surface of 
endothelial cells is accepted as a safe, relevant and accessible receptor for 
targeted drug delivery [1]. ICAM-1, a cell-surface glycoprotein member of the Ig 
super-family, is expressed basally on normal vascular endothelium. Under 
inflammatory conditions, interaction between endothelial cells and blood 
constituents occurs by the up-regulation of intercellular adhesion molecules such 
as ICAM-1 on the surface of endothelial cells and leukocytes [42-43]. This 
mediates the targeted migration of leukocytes into specific areas of inflammation 
[44]. Various ICAM-1 based therapeutic agents for cancer immunotherapy and 
other modes of treatment are used nowadays [45-46]. This mediates the targeted 
migration of leukocytes into specific areas of inflammation [44]. ICAM-1 is 
considered a versatile anchor for targeted drug delivery and various therapeutic 
agents are applied nowadays in the context of oxidative stress, inflammation, and 
thrombosis as well as for cancer immunotherapy and other modes of treatment [1, 
45-46]. Our biomimetic vascular model applies endothelial cell surface ICAM-1 
molecules for targeting drug carriers. ICAM-1 antibody coated particles acts as 
model drug carriers based on ICAM-1:anti-ICAM-1 binding affinity.  
2.5 Influence of vessel geometry in drug carrier distribution   
The human circulatory system consists of large blood vessels such as arteries and 
veins (~15-0.5 mm), and smaller vessels such as arterioles, venules (100-500 µm) 
and capillaries (~10 µm). The distribution of drug particles in a real vascular 
network having a hierarchical geometry will depend on local shear rate, flow 
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velocity, pressure and volume [47]. Our study considers the distribution of nano 
and micron sized particles in a branching channel that mimics the geometry and 
flow conditions of a dividing microvascular network. Microvasculature refers to part 
of the circulatory system consisting of capillaries, arterioles, and venules [48]. 
Microvasculature parameters such as vascular geometry, target-receptor 
expression levels and flow shear rate must be considered while performing in vitro 
tests.   
2.6 Distribution of drug carriers under the influence of RBC 
Drug carriers interact with blood in vivo, a complex bio-fluid consisting of RBCs, 
monocytes, platelets, proteins etc. Blood flow in microvasculature is a two-phase 
flow as the vessel diameter becomes comparable to the size of RBCs. In vitro 
studies on RBC mediated particle delivery have to consider various in vivo 
microvasculature parameters, such as Fåhraeus–Lindqvist effect [49], Segre–
Silberberg effect [50-51], CFL formation [52-54], vessel geometry/bifurcations [55] 
and blunt velocity profile [56-59]. RBCs have a biconcave shape of ~8 µm diameter 
and ~2 µm thickness, and are highly deformable [54, 60]. The flexible RBCs 
migrate radially towards the center region in microvessels based on various 
hemorheology factors such as shear rate, viscosity, hematocrit concentration, 
RBC aggregation and deformability. This results in a RBC concentrated core 
region and a cell-free plasma layer near the vascular wall called CFL [52, 60-61]. 
Particles flowing along with RBCs can diffuse towards these CFL and this will 
influence their distribution and binding dynamics across a channel [62-64].  
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2.7 Current challenges in the study of drug delivery and distribution 
Theoretical modelling studies on drug delivery usually have limited predictive 
capability beyond the parameters used to create the model [65]. Due to bioethical 
regulations and complex physiological conditions, it is challenging to quantify the 
particle delivery process using in vivo animal models [66-67]. Most of the current 
in vitro studies are carried out in flow chambers or channels [68-69], but these 
platforms lack the flexibility to study the effects of branching vascular geometry 
and varying vessel diameter on drug delivery. They also require significant sample 
volumes making it an expensive platform. Targeted drug delivery systems hold 
promise for innovative medical treatment for various pathological conditions. Strict 
regulations are in effect for drug development and testing. Conventional animal 
experimental models to evaluate drug delivery systems raise ethical issues and 
such models also respond different to humans as interspecies predictability is low 
in response to drugs and diseases [13]. In vivo studies also allow only limited 
control of the heterogeneous physical, chemical, and biological parameters 
influencing the blood vessel and present challenges with respect to imaging as 
well [14]. This demands a practical, human-centered and bio-mimetic alternative 
testing platform, which can provide pharmaceutical research greater security and 
shorten the path to new drugs and delivery systems.  
2.8 Microfluidics 
An in vitro bio-mimetic blood vessel should be able to model in vivo physiological 
characteristics like localized pathology microenvironment, relevant flow dynamics 
and vessel shape dimensions. Microfluidic engineering enables integration of 
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precisely controlled flow in channels, whose shape and dimensions can be 
designed to requirement with resolution limits in the micron scale. Microfluidic 
devices made of PDMS are used in this work. They have added advantages like 
rapid prototyping, optical transparency (for effortless imaging), ease of surface 
modification (through protein coating), biocompatibility and ease of integration, 
which facilitates multiplexing and high-throughput analysis [70], along with other 
features like smaller device footprint and reduced reagent volumes. Microfluidics 
have been applied for the past three decades for the development of DNA chips, 
lab-on-a-chip technology, micro-propulsion, and micro-thermal technologies. At 
this size scale faster diffusive mixing of liquids leads to rapid, accurate and highly 
repeatable reactions. These features highlight the potential of microfluidic 
platforms in studying targeted drug particle delivery on a blood vessel mimicking 
model. 
2.9 Biomimetic platforms 
By engineering the right structure and function of biological systems in a device, 
for example; one that contain human cells and mimics the blood vessels and 
tissues of living organs, a new suite of devices is emerging. These are the 
biomimetic organ-on-a-chip platforms. These complex, three-dimensional models 
of human organs are fabricated by relevant principles to design materials and 
devices that transform medical treatment, from the diagnosis of a disease to the 
discovery and delivery of appropriate drugs. In order to more accurately and 
realistically mimic various kinds of in vivo tissues in an in vitro set-up, great effort 
has also been made to imitate fine-structure and natural microenvironment of in 
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vivo tissues. This has lead to better physiologically relevant tissue engineering and 
thus precise reappearance of physiological events and disease patterns in vitro 
[71-72]. Experimentation at the interfaces of biology, engineering and medical 
sciences is critical for this. These platforms have begun to revolutionize the way 
drug testing and disease treatments are being performed now. Traditional cell 
cultures in petri dishes and animal models are used to understand how a human 
body may react to a drug, toxin, or disease. Animal models often fail due to a 
variety of reasons explained previously, costing the pharmaceutical industry 
billions of dollars and years of time. Research that intends to create more realistic 
in vitro living tissue or organ models by accurately mimicking human host 
responses may accelerate the drug screening process with the hopes of fast-
tracking new and potentially life-saving treatments to commercial deployment. 
Successful implementation of this research is anticipated to shorten drug 
development times and lower costs, benefiting both pharmaceutical companies 
and patients. 
 It is a true integration of biology and engineering that makes it possible to design 
“biomimetic” environments that subject the cell to a combination of factors known 
to guide tissue development and help maintain the right phenotype. Novel 
bioengineered culture platforms can provide tight environmental control along with 
the physiological transport and signaling, and thereby enable study of 
development, regeneration, and disease under conditions that predict the 
human in vivo context. In this study we developed an endothelial cell coated blood 
vessel biomimetic model. It has an upper and lower channel separated by a semi-
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permeable, porous, cell culture friendly membrane. Specific endothelial cells can 
be grown on the membrane, which can be cultured under in vivo levels of flow and 
precisely controlled supply of essential biomolecules and external cues. The 
channels are designed such that a section of the upper channel can be accessed 
from the lower channel through the semi-permeable membrane. This facilitates an 
access to the blood vessel model from the lumen (inside the blood vessel) side 
and the ablumen (from the tissue) side, to provide physiologically relevant external 
cues in a spatially controlled localized way. This platform provides us the ability to 
draw physiologically relevant biological conclusions.  
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Chapter 3 
Model 1: endothelial cell receptor protein (ICAM-1) coated 
microvasculature mimicking platform 
3.1 Introduction 
This section studies the binding distribution of anti-ICAM-1 coated particles on an 
ICAM-1 protein coated microfluidic device. Various factors like, vessel geometries 
(straight and branched channels), flow shear rates (200-1600 s-1), particle flow 
along with RBCs, particle size (210 nm and 2 µm), and particle ligand coating 
density, that influence particle binding distribution are analyzed. Around 10% 
higher particle binding density is observed at bifurcation regions of the mimetic 
microvasculature geometry compared to straight regions. Particle binding density 
is found to decrease with increased shear rates.  RBCs enhance particle binding 
for both 210 nm and 2 µm. The particle binding density increases about 2-3 times 
and 6-10 times when flowing in whole blood at 25% RBC concentration compared 
to the pure particle case, for 210 nm and 2 µm particles respectively. With RBCs, 
the binding enhancement is more significant for 2 µm particles than that for 210 
nm particles, which indicates an enhanced size dependent exclusion of 2 µm 
particles from the channel center to the CFL. Increased particle antibody coating 
density leads to higher particle binding density for both 210 nm and 2 µm particles.  
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3.2 Methods 
3.2.1 Fabrication of microfluidic device 
The required microfluidic design is photo-lithographically patterned on a silicon 
wafer using SU-8 2050 photoresist. Microfluidic devices are fabricated using 
Sylgard 184 PDMS. PDMS base is mixed with its cure at 1:10 (v/v) ratio following 
the basic techniques in soft lithography [35]. The PDMS mixture is poured on the 
silicon wafer, which acts as the master template. The hard PDMS layer is peeled 
out after baking and the features are inspected. The microfluidic device is made 
by binding the PDMS pattern on a clean glass slide after exposing them to oxygen 
(O2) plasma. The flow channels are 100 µm wide and 100 µm in height. Both 
straight and bifurcating features are included in the design. The bifurcating 
channels have a branching angle of 60°.  
3.2.2 ICAM-1 functionalized PDMS substrate  
PDMS devices were coated with ICAM-1 as previously reported[10]. After binding 
with glass the PDMS microfluidic devices were silanized with 3-
aminopropyltrimethoxysilane to improve protein adsorption. After washing the 
device with an adsorption buffer (0.1M NaHCO3, pH 9.2), the devices were 
incubated for 2 hrs at room temperature with saturating concentration of protein G 
in adsorption buffer (100 µg/ml). ICAM-1 Fc chimera protein solution in PBS (100 
nM) was introduced after washing the substrates three times with PBS to remove 
any excess protein G. The devices were incubated with ICAM-1 for 1 hr at room 
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temperature. The microfluidic chips were purged with 1% BSA containing 0.05% 
Tween20 one hour prior to testing.  
3.2.3 Substrate ICAM-1 density characterization  
In order to quantify the ICAM-1 protein density on the PDMS surface, ELISA was 
performed using an HRP-conjugated anti mouse IgG1 antibody. ELISA reaction 
was carried out in a 12-well plate and PDMS coated 22 mm circular glasses were 
used. The technique for substrate ICAM-1 characterization was performed as 
reported in literature [10].  
Silicone isolators (Grace Bio Labs) were used to assure that the same volume of 
reagents were applied on PDMS coated glass as in the microfluidic device, to 
maintain the same surface area to volume ratio. Once the PDMS coated cover 
slips were coated with ICAM-1 Fc protein, they were blocked before silicone 
isolators were removed. This was followed by incubation with mouse anti-ICAM-1 
at 2 µg/ml for 1 hr at 4 ̊C, and incubation with HRP-conjugated mouse antibody 
(1:1000 dilution). Each step was followed by washing with ice cold PBS. After the 
final wash step, the cover slips were placed in the well plate. Amplex Ultra Red 
reagent was used to initiate the ELISA reaction and was allowed to incubate for 10 
min at room temperature. Fluorescence was measured on a microplate reader at 
544 nm excitation/590 nm emission. The readings were compared to a calibration 
curve and the ICAM-1 surface density was calculated. 
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3.2.4 Anti-ICAM-1 coated micro/nano particles 
Neutravidin coated 210 nm and streptavidin coated 2 µm fluorescent particles were 
diluted to 1010 and 108 particles/ml respectively using Block-Aid, and sonicated 
for 5 minutes. Biotinylated antibody (anti-ICAM-1, control or both) was added next 
after diluting the particles in 1% BSA. The 210 nm particles were diluted to 109 
particles/ml and the 2 µm particles were brought down to 107 particles/ml and the 
antibody concentration was kept to a total of 10 µg/ml. Particles were incubated 
for 3 hours while shaking at room temperature and the unbound antibody was 
removed by centrifugation. The particles were washed in 1% BSA solution to 
remove any leftover unbound antibody and then diluted to working concentration 
for the flow tests. Particle concentration was analyzed on a microplate reader at 
485 nm excitation/530 nm emission and compared to a calibration curve 
constructed from stock particle solution.  
3.2.5 Particle anti-ICAM-1 density characterization 
An ELISA was performed using HRP conjugated anti-mouse k-light chain specific 
monoclonal antibody to characterize the particle surface antibody density. The 
specificity of the reagent to mouse antibody light chain provides a direct 
measurement of the anti-ICAM-1 binding sites available on the particle. Particles 
were incubated with 5% HRP conjugated anti-mouse k-light chain specific 
monoclonal antibody for 30 minutes, followed by washing with 1% BSA solution 
and clearing out of unbound antibody through centrifugation. 50 µl of the particle 
solution were loaded on a 96-well plate and the particle concentration was 
analyzed. Then 50 µl of Amplex Ultra Red reagent was added to each well and the 
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HRP-substrate reaction was allowed to proceed for 10 minutes at room 
temperature. The fluorescence intensity of the particle sample with Amplex Ultra 
Red reagent was observed on a microplate reader at 544 nm excitation and 590 
nm emission. The fluorescence intensities were converted to the number of HRP 
molecule using the calibration curves prepared using biotinylated-HRP conjugation 
to the neutravidin/streptavidin coated particles.  Assuming a 1:1 binding ratio 
between anti-ICAM-1 and secondary antibody, the anti-ICAM-1 density on the 
particles were determined. In order to make sure the reaction mechanism and 
kinetics involved for anti-ICAM-1 binding on particle and while performing ELISA 
are same in the nano and micron sized particles, we compared the fluorescence 
intensity for similar anti-ICAM-1 density case of both particle sizes. This helps to 
make sure that the different protein and antibody binding reactions involved while 
performing ELISA doesn't vary based on particle size and other possible steric 
hindrance factors. 
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3.3 Results and Discussion 
3.3.1 Characterization of particle and PDMS substrate protein densities 
ICAM-1 coating density of the microfluidic channels was kept the same for all flow 
cases. It was determined by applying ELISA on PDMS coated glass slides as 
described before [68]. ICAM-1 density on our microfluidic channels was measured 
to be 121±12 sites/µm2.  
NeutrAvidin coated 210 nm and Streptavidin coated 2 µm particles were 
functionalized with anti-ICAM-1 based on biotin-avidin chemistry. The anti-ICAM-
1 coating density on the particle was determined using ELISA. Complete saturation 
of antibody coating on 210 nm particles produced 239.3±25 anti-ICAM-1/particle. 
This was brought down to 157.9±19 and 78.6±9 anti-ICAM-1/particle. This 
corresponds to 1905.3±199/µm2 for the maximum antibody density case, followed 
by 1257.1±151 and 625.8±71 anti-ICAM-1/µm2. The 2 µm particles were tuned to 
have a density of 12184.1±264 and 2767.9±103 anti-ICAM-1/particle which 
corresponds to 1199.2±25 and 272.2±10 anti-ICAM-1/µm2 respectively. Particle 
coating density was tuned using biotinylated goat IgG control antibody.  
3.3.2 Specificity of anti-ICAM-1 coated particle binding to ICAM-1 coated surface 
The specificity of particle binding to ICAM-1 coated surfaces was studied by 
comparing the binding of anti-ICAM-1 coated particles to negative control case 
(Figure 3) 210 nm and 2 µm sized particles were coated with 1905.3 and 1199.2 
anti-ICAM-1/µm2 respectively. Both pure buffer and RBC 25% cases were 
performed at a shear rate of 200 s-1. Particles specifically bound to ICAM-1 coated  
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microfluidic channel with around ten times higher density when compared to the 
negative control case, for both pure buffer and with RBCs cases.  
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Figure 3: Binding density of anti-ICAM-1 and negative control (Goat IgG control) 
antibody coated (A) 210 nm particles and (B) 2 µm particles under 200 s-1 shear 
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3.4 Conclusion 
A bifurcating microvasculature mimicking PDMS microfluidic platform has been 
developed in this work. We are capable of tuning the channel shape, size and 
specific receptor protein coating based modelling of desired blood vessel state with 
control of protein coating density. We also produced drug carrier modelling 
particles coated with specific ligand molecules with the ability to control the coating 
density. The channels were coated with ICAM-1 and the protein density was set to 
model a microvessel in an inflamed state. The 210 nm and 2 µm particles were 
coated with ICAM-1 antibody at different coating densities and characterized. The 
specificity tests of anti-ICAM-1 coated particle binding to ICAM-1 coated surfaces 
have also been performed using anti-ICAM-1 and negative control (Goat IgG 
control) antibody coated 210 nm particles and 2 µm particles binding under flow 
test at 200 s-1 shear rate for both pure buffer and RBC 25% flow cases. 
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Chapter 4 
Characterization of targeted nano and micro 
particle delivery in microcirculation  
4.1 Introduction 
This section studies the binding distribution of anti-ICAM-1 coated particles on 
ICAM-1 protein coated microfluidic device. Various factors like, vessel geometries 
(straight and branched channels), flow shear rates (200-1600 s-1), particle flow 
along with RBCs, particle size (210 nm and 2 µm), and particle ligand coating 
density, that influence particle binding distribution were analyzed. Around 10% 
higher particle binding density is observed at bifurcation regions of the mimetic 
microvasculature geometry compared to straight regions. Particle binding density 
is found to decrease with increased shear rates.  RBCs enhance particle binding 
for both 210 nm and 2 µm. The particle binding density increases about 2-3 times 
and 6-10 times when flowing in whole blood at 25% RBC concentration compared 
to the pure particle case, for 210 nm and 2 µm particles respectively. With RBCs, 
the binding enhancement is more significant for 2 µm particles than that for 210 
nm particles, which indicates an enhanced size dependent exclusion of 2 µm 
particles from the channel center to the CFL. Increased particle antibody coating 
density leads to higher particle binding density for both 210 nm and 2 µm particles.  
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4.2 Methods 
4.2.1 Microfluidic flow test cases 
 
The microfluidic device is designed to mimic the geometry of typical 
microvasculature. The design contains both straight and branching sections. The 
bifurcating angle was decided from measurements on arterial microcirculation 
system, theoretical values based on Murray's law and the bifurcation angle 
relationships of minimum work principle [73]. Particle binding density at straight 
and branching regions are calculated separately. The area considered to be the 
bifurcation section starts from the point where straight channels begin to bifurcate 
and ends in the daughter channel at a length of 2.5 times the vessel diameter from 
the apex of bifurcation (Figure 4). This was based on the principle that it takes 
about 2 times the distance of vessel diameter for the re-establishment of parabolic 
flow after bifurcation  [74]. 
Anti-ICAM-1 coated particles were subjected to flow through ICAM-1 modified 
microfluidic devices at different shear rates between 200 and 1600 s-1. This 
corresponds to physiologically relevant values observed in the microvessels [75-
76]. The binding session was followed by a PBS only flushing session to remove 
unbound particles and to study particle detachment. This is performed at the same 
shear rate used to study particle attachment. The shear rate of flow in daughter 
channels are half that of the parent channel after branching, as they have the same 
dimension as the parent channel and also the daughter channels are of the same 
length. The particle concentration is kept at 108/ml and 106/ml for 210 nm and 2 
µm particles respectively. The duration of flow was fixed at 15 and 20 minutes for 
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210 nm and 2 µm particles respectively. These time periods and particle 
concentrations were decided to accommodate all particle binding studies to a 
window where the binding rate was steady and the binding density could be 
practically quantified. Since the particle concentration and flow time are kept 
constant for all shear rates, the numbers of total particles introduced into the 
channels increase with shear rate. This factor is considered while calculating the 
particle binding density. The results were normalized to a total particle count of 
106/flow case for all studies performed. The normalization process is explained in 
the supplementary information (Table S7).  To compare the effect of particle size 
on binding, few flow cases were performed at 106/ml concentration for 210 nm 
particles. 
Particle binding density was computed from confocal scans of the bottom surface 
of the channel. Time lapse imaging was performed in order to determine the 
attachment and detachment profile of the particles under different flow conditions. 
Analysis of particle binding was performed on a high resolution laser confocal 
fluorescence microscope (FV1000-IX81, Olympus). The particle binding density is 
computed at the center section of the bottom channel surface. The center section 
of the channel is decided by excluding areas within 25% of the channel width from 
edges. Flow conditions are more stable at the center compared to the edges of the 
channel and thus the variation in particle binding density is low here.  
Flow tests were performed with particles diluted in pure buffer and whole blood 
with 25% RBC hematocrit, which represents the average hematocrit in 
microvessels [77].  Whole blood with 40% RBC concentration was brought down 
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to 25% by diluting in human blood plasma. The RBC flow case studies the 
influence of RBCs on particle diffusion and binding in microvessels. Blood plasma 
can contain soluble factors like CAM molecules which vary from donor to donor 
and can possibly affect the binding of particles on ICAM-1 modified substrates [78-
79]. Thus the same pool of plasma and whole blood was used for all RBC flow test 
cases and the tests were performed the same day to normalize the effect of these 
soluble factors. 
Fluid flow was generated using a programmable syringe pump (Harvard 
Apparatus), which controls the volumetric flow rate that is proportional to the wall 
shear rate. The wall shear rate   was derived from the volumetric flow rate 	 using 
the following relation: 
 
Where H is the height and W is the width of the microfluidic device. 'f' is a geometry 
factor derived from the ratio of width to height. In this study, a microfluidic channel 
with a height and width of 100 µm is used, thus f=0.5928 [80]. 
 
γ= (6Q/H
W)	(1 + H/W)	f ∗ (H/W) 
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Figure 4: (A) CAD design of microchannel geometry, enlarged part illustrates the 
straight and bifurcation section of the channel; (B) The flow test set-up. 
The effect of asymmetric flow between daughter branches on particle binding was 
also studied. For daughter channels with identical width and height, the 
relationship between flow rate and resistance is simplified to LaQa=LbQb [81] 
(La,Qa,Lb and Qb are the length and flow rate of the daughter channels a and b 
respectively). Based on this, a change in length in one of the daughter channel 
would proportionally change the flow rate in that channel. A change in flow rate 
would translate to a direct proportional change in shear rate of flow (Table 1 on 
page 25). Channels were designed to generate different flow distribution in the two 
B A
650 µm 
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daughter channels as shown in Table 1. The shear rate in one of the daughter 
channel is half of the other. Only straight sections of both the parent and daughter 
channels (after branching) were scanned to quantify the particle binding density in 
this case. Particle binding was quantified at the same distance from branching 
apex for both the daughter channels. 
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4.3 Results and Discussion 
 
4.3.1 210 nm and 2 µm particle binding distribution 
In order to study the binding and flow dynamics of particles studies were performed 
on 210 nm and 2 µm particles suspended in both pure buffer and whole blood 
(25% RBC). Binding of particles on both straight and bifurcating regions of the 
channel was examined. The binding density of 210 nm and 2 µm particles 
decreases with shear rate in both straight and branching channels for pure buffer 
case ( 
Figure 5, Figure 9; A and C). This can be explained by the decreased available 
time for particle to diffuse/marginate toward the wall under increased flow rate.  
However, for the RBC 25% flow case ( 
Figure 5, Figure 9; B and D) an increase in binding density is observed till the 550 
s-1 shear rate.  
The decrease in particle binding density with an increase in shear rate can be 
explained as the binding process being in a reaction limited regime as explained 
The RBC 25% flow case showed ~2-3 times enhanced binding density when 
compared to pure buffer flow case for 210 nm particles, with the difference 
decaying with increase in shear rate ( 
Figure 5). The 2 µm particles showed around 6-10 times increase in binding density 
when suspended in 25% RBC depending on the shear rate (Fig 5 B and D) when 
compared to the pure buffer case. This increase in particle binding density can be 
explained by the availability of more particles close to the near wall region when 
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flowing with RBCs. The presence of RBCs pushes out particles from the channel 
center towards the near wall CFL region, thereby bringing more particles closer to 
the ICAM-1 coated surface. As the shear rate increases from 550 s-1 to the higher 
shear regime, particle binding density drops for the RBC case like the pure buffer 
case. This is likely because the localization of particles to the CFL saturates or 
drag force produced by flow shear exceeds adhesion force between ICAM-1 and 
anti-ICAM-1 receptor ligands. 
           
        
Figure 5: Normalized particle binding density (#/mm2) at shear rates 200-1600 s1;  
at branching section of channels under (A) pure buffer flow and (B) RBC flow for 
210 nm particles; at straight section of channels under (C) pure buffer flow and (D) 
RBC flow for 210 nm particles. Binding densities are plotted for 1905.3, 1257.1 
and 625.8 anti-ICAM-1/µm2 particle antibody densities.  Error bars represent 
standard deviation for three independent flow cases each. 
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Figure 6: Particle binding density (#/mm2) at shear rates between 200-1600 s-1 
under RBC flow for 210 nm particles at (A) branching section of channels and (B) 
straight section of channels without data normalization; (C) Particle binding density 
of 210 nm particles with an anti-ICAM-1 coating density of 1905.3/µm2 under  RBC 
flow at 200 s-1 and 550 s-1 shear rate without normalization. 200 s-1shear rate case 
was subjected to an extended flow of 45 minutes to match with the total number of 
particles flown for the 550 s-1case (15 minutes flow). 
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A 
B 
C 
Figure 7: (A) Zoomed in image of 210 nm particle binding at 1250 s-1 shear rate for 
1905.25/µm2 anti-ICAM-1 particle coating density; (B) Phase contrast  image of Fig 
S2 A ; (C) 6X times zoomed in image scan of Fig S2 A showing each 210 nm 
particle. 
Figure 8: Confocal microscopy scan of free suspending 210 nm particle localization 
to the near wall region for: (A) Pure buffer case at 200/s shear rate (B) RBC 25% 
case at 200/s shear rate (C) RBC 25% case at 550/s shear rate (D) RBC 25% case 
at 900/s shear rate in the 100 µm wide microfluidic channel at a particle 
concentration of 108/ml. The image is a sum of the stack of confocal scan images 
from 1 µm above the channel base to a height of 5 µm in the z direction.    
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The decrease in particle binding density with an increase in shear rate can be 
explained as the binding process being in a reaction limited regime as explained 
in Namdee et al's and Charoenphol et al's work [82-83]. A similar drop in particle 
binding density for 210 nm particles with increase in shear rate is also observed in 
Haun and Hammer's work [68]. At higher shear rates the larger drag force can 
easily wash away larger attached particles regardless of anti-ICAM-1 coating 
density. Work by Patil et al. found the shear rate required to set in motion a firmly 
adhered microsphere to decrease with increasing microsphere diameter [84]. This 
is a result of same shear producing higher drag force on larger particles. Thus 
shear rate based detachment effects are more dominant in the larger 2 µm 
particles compared to the 210 nm ones. This is consistent with existing literature 
[84-86].  
The binding density also increases with particle anti-ICAM-1 density for all flow 
cases and both particle sizes under study. Higher antibody coating density 
provides a better possibility of enough ligand-receptor bond formation to assure 
firm attachment of the particles to the ICAM-1 coated surface [68, 87]. For 2 µm 
particles at 200 s-1 shear rate there is about five time increase in particle binding 
density for the 1199.2/µm2 case over the 272.2/µm2 anti-ICAM-1 density case 
(Figure 9 B and D). However such antibody coating density induced increase in 
binding density decays at higher shear rates for the 2 µm particles. It is observed 
that at 1600 s-1 shear rate both particle anti-ICAM-1 coating densities show similar 
binding density. At lower shear rates the particle binding is influenced more by the 
receptor-ligand interaction. However at higher shear rates the 2 µm particle binding 
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process is influenced more by the availability of particles near the wall region and 
the detachment of particles by the high flow shear rate. In terms of channel 
geometry, 10% higher NP binding density is observed at bifurcations compared to 
straight channels. Flow disturbances or alteration of flow at bifurcation regions lead 
to enhanced particle collision with the wall, which enhance binding [88-91]. 
                    
 
              
Figure 9: Normalized particle binding density (#/mm2) at shear rates between 200-
1600 s-1; at branching section of channels under (A) pure buffer flow and (B) RBC 
25% flow for 2 µm particles; at straight section of channels under (C) pure buffer 
flow and (D) RBC 25% flow for 2 µm particles. Binding densities are plotted for two 
different anti-ICAM-1 particle coating densities; 1199.2 and 272.2 anti-ICAM-
1/µm2. Error bars represent standard deviation for three independent flow cases 
each. 
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4.3.2 Comparison between binding of 210 nm particle and 2 µm particles 
A comparison is performed on the binding density characteristics of 210 nm and 2 
µm particles with similar anti-ICAM-1 densities (1257.1 and 1199.2 anti-ICAM-
1/µm2 for 210 nm particles and 2 µm particles respectively) in this section.  
Fig 7 A and B compares the particle binding density for 210 nm and 2 µm particles 
for pure buffer and RBC 25% flow case respectively. For the RBC flow case 2 µm 
particles show higher binding for shear rates up to 550 s-1. This is constant with 
work by Namdee et al. [83] who also observes increased binding for 2 µm particles 
compared to 200 nm when flowing in a 30% RBC solution. For higher shear rates 
the larger drag force acting on bigger 2 µm particles leads to detachment and thus 
produces less particle binding compared to 210 nm particles.  
For the pure buffer case the binding density of 210 nm particles is 2-3 times higher 
than 2 µm particles. However, it should be noted that this study was conducted at 
a particle concentration of 108/ml for the 210 nm particles and 106/ml for the 2 µm 
particles. In order to understand the effect of this 100 times increase in particle 
concentration on binding density, we also did flow tests at 106/ml particle 
concentration for 210 nm particles. It was observed that both the pure buffer and 
RBC 25% flow cases produced particle binding that didn't vary significantly with 
changes in factors such as shear rate, particle antibody density or flow with RBCs 
(data not shown). To understand this we measured the localization of 210 nm 
particles at this concentration near the wall region for the pure buffer and RBC 25% 
case using confocal microscope scanning. No significant fluorescence signal was 
observed near the wall region when compared to the 108/ml case (Fig S3), which 
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indicates the lack of particle localization to near wall CFL region. Our study was 
conducted at a particle concentration of 108/ml for the 210 nm particles and 106/ml 
for the 2 µm particles and the results were normalized to 106 particles/flow case 
for both particle sizes. Thus this 100 times higher 210 nm particle concentration 
should have translated to the higher particle binding density observed in the pure 
buffer case. The work by Namdee et a.l [83] also observes an increase in particle 
binding density with increased particle concentration for the pure buffer case.  
Fig. 7C compares the magnitude of increase in particle binding density for RBC 
25% whole blood case compared to the pure buffer case for the 2 µm and 210 nm 
particles with similar anti-ICAM-1 density. This is done by calculating the ratio of 
increase in particle binding density for the RBC 25% case over the pure buffer 
case under the same shear rates for both 2 µm and 210 nm particles. 2 µm 
particles show almost three times increase in binding ratio when flowing with RBCs 
compared to similar 210 nm particle case for shear rate up to 550 s-1. Even at high 
shear rates above 550 s-1 2 µm particles show almost twice the binding ratio 
compared to 210 nm particles, although detachment becomes dominant as shear 
rate increases.  
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Figure 10: Normalized particle binding density (#/mm2) for 210 nm (1257.1 anti-
ICAM-1/µm2) and 2 µm (1199.2 anti-ICAM-1/µm2) particles are compared for (A) 
pure buffer flow case and (B) RBC 25% flow case at different shear rates; (C) 
Comparing ratio of particle binding density of RBC flow case to pure buffer flow 
case for 210 nm (1257.1 anti-ICAM-1/µm2) and 2 µm (1199.2 anti-ICAM-1/µm2)  
particles at different shear rates; 
Prominent binding is observed for the 2 µm particle for RBC 25% flow case when 
compared to 210 nm particles due to size based enhanced particle margination to 
the CFL. Particles or cells marginate toward the near wall cell free region when 
flowing along with RBCs [82, 92-94]. This occurs because of their interaction with 
RBCs and the deformation of the RBCs in flow. The collision between the 
deforming RBCs during flow easily pushes out particles or cells of size comparable 
to RBCs to the cell free plasma region. In Eckstein et al's work, a size selective 
enhanced exclusion of beads of diameter greater than 2.2 µm was observed [95]. 
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In this confined region the interaction between the RBCs and particles increases 
the collision between the anti-ICAM-1 coated particles and the ICAM-1 coated 
PDMS surface and this leads to increased particle binding. A similar phenomenon 
was observed in other studies [82-83, 96]. Comparatively only a smaller 
percentage of 210 nm particles marginates toward the near wall region and most 
of them tend to flow along with RBCs in the core region because of their smaller 
size [95]. This along with their smaller size compared to the CFL (2-10 µm) [53, 
97] produces lower increase in particle binding density compared to the 2 µm 
particle case. 
4.3.3 Daughter channels with asymmetric flow velocity 
In micro circulation, daughter channels can have differences in flow velocities 
between them after branching [55]. In order to study the effect of this asymmetric 
flow distribution between daughter branches on particle binding, we conducted 
tests in channels of geometries that produce this effect. The parent and daughter 
channels were of the same cross sectional area, but of different lengths. This 
would produce a variation in flow rate between the daughter channels such that 
the shear rate of one daughter channel would be half of the other. Daughter 
channel 'b' had half the length of channel 'a' (Figure along with Table 1) for this 
purpose. Table 1 lists the shear rates of flow in parent and the two daughter 
channels for the three flow cases performed. Flow tests were conducted for 210 
nm and 2 µm particles having an anti-ICAM-1 coating density of 1905.3/µm2 and 
1199.2/µm2, suspended in 25% hematocrit whole blood.  
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Table 1: Shear rates in the parent channel and in daughter channels a and b for 
the different flow cases studied. Image shows the top view of the flow channel 
design that produces asymmetric flow in daughter channels 
 
 
The binding density for 210 nm particles at a concentration of 108/ml is given in 
Fig 8 A. For the three flow cases at a shear rate of 200, 900 and 1600 s-1 in the 
parent channel, higher particle binding density is observed in the daughter channel 
when compared to the parent channel. Daughter channel 'a' has 1/3rd and 'b' has 
2/3rd the shear rate of the parent channel and between them channel 'b' has twice 
the shear rate of channel 'a'. The daughter channel 'a' shows almost 2 times higher 
binding density than channel 'b'. This can be explained by channel 'a' having half 
the flow shear rate of channel 'b'. 210 nm particles show similar increased binding 
density with decreased shear rate pattern as discussed earlier (Fig. 3). 
For the 2 µm particles almost similar particle binding density was observed in 
parent and daughter channels for all shear rates other than for 1600, 1066.6 and 
900 s-1 (Fig 8 B) after normalization. These results match well with what we saw 
for RBC 25% case of 2 µm particles at different shear rates for a particle anti-
ICAM-1 density of 1199.2/µm2  (Fig 5). It is observed that the particle binding 
density begins to decrease dramatically for shear rate above 600 s-1. This is 
because of large drag force from these higher shear rates acting on the particle, 
Flow 
case 
Shear rate 
in parent 
channel 
Shear rate in 
daughter 
channel a 
Shear rate in 
daughter 
channel b 
1 200 66.6 133.3 
2 900 300 600 
3 1600 533.3 1066.6 
Parent 
Channel b 
Channel a 
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which leads to decreased receptor ligand reaction and also increased particle 
detachment. 
     
 
Figure 11: Normalized particle binding density in parent channel and daughter 
channels a and b for the asymmetric flow case under RBC flow for (A) 210 nm 
particles at 1905.3 anti-ICAM-1/µm2 and (B) 2 µm particles at 1199.2 anti-ICAM-
1/µm2. 
In flow channels where the daughter branches have different flow velocities, there 
might be a preferential, non-linear distribution of RBCs/particles to the daughter 
branch with the faster flow [98-100]. Thus the daughter channel with higher flow 
velocity/shear rate ends up receiving more RBCs/particles. We didn't observe such 
a preferential flow of particles to the daughter channel having the higher shear rate. 
This could be because our particle size is much smaller when compared to the 
flow channel cross section. Our 2 µm particle is only 0.02 times the size of the 
channel with a length and height of 100 µm each (210 nm particle becomes more 
insignificant). The above mentioned non-linear distribution are prominent only 
when the diameter of RBC/particle is of the same range as the channel diameter 
[99]. 
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4.3.4 Attachment and detachment profiles  
210 nm particles 
To provide a more quantitative and physical understanding of particle binding 
process, attachment and detachment rates of particles are derived from the 
particle binding time histories.   The time history profiles of particle density during 
attachment and detachment processes in pure buffer flow are shown in Fig S4. 
Attachment and detachment processes for NP of three different anti-ICAM-1 
densities are compared.  
 
  
 
Figure 12: Attachment and detachment time history profile of normalized particle 
binding density data for 210 nm particles at shear rates (A) 200 s-1 (B) 550 s-1 (C) 
900 s-1 (D) 1250 s-1 & (E) 1600 s-1. All three anti-ICAM-1 particle densities of 
1905.25, 1257.1 and 625.8 /µm2 are studied. Dashed green line indicates the start 
of detachment period. Error bars represent standard deviation for three 
independent flow cases. 
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Time lapse microscopy was performed on the 210 nm particles binding in the 
microfluidic channel. Images were taken every 2.5 minutes and binding profile for 
a total time of 15 minutes was analyzed. This was followed by a washout period of 
10 minutes at the same shear rate to clear unbound particles in solution and to 
study particle detachment process. During the first 15 minutes of attachment, 
particle binding density increases linearly with time for a certain shear rate. The 
binding rate is calculated from the slope of the binding density time history profile.  
The binding rate is found to decrease with increased shear rate (Fig. S6 A). 
Increased anti-ICAM-1 density on the particle leads to a higher binding rate. 
Particle detachment was observed when buffer solution was flowed through the 
microfluidic channel after 15 minutes. For 210 nm particles a detachment of ~4-
6% of particles occurred when compared to the total number of attached particles.  
This indicates that 210 nm particles are hard to be detached once they adhered to 
the surface. This is likely due to the small size of the particle that leads to small 
drag force acting on them and strong ligand-receptor binding even through the 
formation of a single bond. 
2 µm particles 
Similar to 210 nm particles, the attachment and detachment rates of 2 µm particles 
in pure buffer flow are derived from the particle binding time histories. Time lapse 
microscopy on the particle binding in the microfluidic channel was performed every 
2.5 minutes. Binding profile for a total of 20 minutes was analyzed and this was 
followed by a washout period of 10 minutes to clear unbound particles in solution 
and to study particle detachment process. The first 20 minutes of attachment 
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showed particle binding density increasing linearly with time for a certain shear 
rate (Fig S5). The binding rate is calculated from the slope of the binding density 
time history profile.  The binding rate is found to decrease with increased shear 
rate (Fig. S6 C). Increased anti-ICAM-1 density on the particle leads to higher 
binding rate. Particle detachment was observed when pure buffer solution was 
flowed through the microfluidic channel after 20 minutes of particle attachment 
study. 2 µm particles have high detachment rate, much higher than the attachment 
rate (Fig S6 C & D). This indicates shear based drag force acting on particles is 
dominant on the 2 µm particles compared to 210 nm particles. 
    
    
Figure 13: Attachment and detachment time history profiles of normalized particle 
binding density for 2 µm particles at shear rates (A) 200 s-1 (B) 550 s-1 (C) 900 s-
1 (D) 1250 s-1 & (E) 1600 s-1. Both anti-ICAM-1 particle densities of 1199.2 and 
272.2 / µm2 are studied. Dashed green line indicates the start of detachment 
period. Error bars represent standard deviation for three independent flow cases. 
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4.3.5 Derivation of attachment and detachment rates from experimental data 
To retrieve NP adhesion and detachment rate, a first order particle adhesion 
kinetics is used to fit the binding history: 
 
0
s
a d s
c
k c k c
t
∂
= −
∂                                                                           
Where 0
c
is the initial bulk concentration of the NPs, s
c
is surface concentration of 
binding NPs, 
 and 
a d
k k
are attachment and detachment rates respectively. During 
early stage of binding, s
c
is very small, thus, detachment can be neglected. The 
accumulation of NPs bonded to the surface can be found as 0s a
c k c t=
. Through 
data fitting, the adhesion rates under different shear rates and antibody densities 
are plotted in Fig S6. As shown from the figure, the adhesion rate is found to 
decrease with shear rates and increases with antibody density coated on particle 
surface.  210 nm particles are more than one order of magnitude higher in 
adhesion rate compared to 2 µm particles for pure buffer case.  
Likewise, setting ka=0, 
s
d s
c
k c
t
∂
=−
∂ , the detachment rate can be found by fitting the 
detachment curve using formula exp( )s dc k t const= − + . The detachment rate is found 
to increase with shear rate and decrease with antibody density.  It should be noted 
that 2 µm particles with antibody density of 272.2 /µm2 are all washed away thus 
have no data available at shear rate of 1600 s-1.  
 
 
57 
 
 
 
Figure 14: Particle attachment and detachment rates for 210 nm (A-B) and 2 µm 
particles (C-D), respectively. 
4.3.6 Normalization process to bring all flow cases to a total particle count of 
106/flow case 
• Consider the flow rate to be 1 ml/hr to achieve 200/s shear rate. 
• Particle concentration: 108/ml 
• Flow time: 10 minutes 
 
 
 
 
 
 
 
0 500 1000 1500 2000
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
x 10
-7
 Shear rate(s-1)
 A
d
h
e
s
io
n
 r
a
te
(m
/s
)
 
 
 1905/µm
2
 1257/µm
2
 626/µm
2
0 500 1000 1500 2000
0.5
1
1.5
2
2.5
x 10
-5
 Shear rate(s-1)
 D
e
ta
c
h
m
e
n
t 
ra
te
(s
-1
)
 
 
 1905.25/µm
2
 1257.1/µm
2
 625.8/µm
2
0 500 1000 1500 2000
0
0.5
1
1.5
2
2.5
3
3.5
x 10
-8
 Shear rate(s-1)
 A
d
h
e
s
io
n
 r
a
te
(m
/s
)
 
 
 1199.2/µm
2
 272.2/µm
2
0 500 1000 1500 2000
0
0.5
1
1.5
2
2.5
3
x 10
-3
 Shear rate(s-1)
 D
e
ta
c
h
m
e
n
t 
ra
te
(s
-1
)
 
 
 1199.2/µm
2
 272.2/µm
2
A B 
C D 
58 
 
Table 2: Detailed steps of the normalization process performed to bring all flow 
cases to a total particle count of 106/flow case 
Shear 
rates 
Corresp
onding 
flow rate 
Total 
particle 
flown in 10 
minutes 
Total particle 
binding 
(hypothetical) 
Particle binding after 
normalization to 106 
particles/flow case i.e. 
		  		!" # ∗ 10
% 
200/s 1 ml/hr 16666666.6 10000000 600000 
900/s 4.5 ml/hr 75000000 30000000 400000 
1600/s 9 ml/hr 150000000 50000000 333333.3 
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4.4 Conclusion 
The binding density of anti-ICAM-1 coated 210 nm and 2 µm particles on ICAM-1 
modified PDMS microfluidic devices is characterized in this work. The study 
employs various factors that influence particle distribution and binding such as flow 
shear rate, particle size, flow along with RBCs, vessel geometry, antibody coating 
density on the particle, particle concentration and effect of asymmetric flow 
distribution between daughter channels. 
The particle binding densities for both 210 nm and 2 µm particles decrease with 
increased shear rate for pure buffer case. This can be explained by the decreased 
available time for particle to diffuse/marginate toward the wall under increased flow 
rate. RBCs play an important role in particle binding and distribution pattern. Both 
210 nm and 2 µm particles show enhanced binding density at 25% hematocrit RBC 
flow. 210 nm particles showed 2-3 fold increase in binding under blood flow till a 
shear rate of 550 s-1 and 2 times increase in binding for much higher shear rates 
when compared to the pure buffer case. Similarly, 2 µm particles show around 6-
10 fold increase in binding for shear rates up to 550 s-1 and around 4 times 
increased binding for much higher shear rates when compared to the pure buffer 
case. The steep drop in binding density observed for the RBC 25% flow case of 2 
µm particles beyond a shear rate of 550 s-1 is a result of high shear flow induced 
large drag force acting on the bigger 2 µm particles leading to their detachment. 
The smaller 210 nm particles have much lower drag force acting on them 
compared to the 2 µm particles.  
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In terms of vessel geometry, both particles show a slight increase in binding 
density at the bifurcation region compared to the straight channels. This is 
observed for both pure buffer and RBC 25% flow case. Disturbance of flow at the 
bifurcation region leads to enhanced particle collision with the wall and results in 
higher particle binding density. This contributes to the enhanced binding observed 
at the branching section. Higher antibody coating density facilitates more rapid 
formation of sufficient ligand-receptor bonds to assure firm attachment of particles. 
Higher particle anti-ICAM-1 coating density thus increases binding density, except 
for high shear rate cases for 2 µm particles where shear based detachment drag 
force nullifies the enhancement brought by  increased antibody density.  
The results produced in our study can be related to clinically relevant drug delivery 
systems like liposomes[101], trimethyl chitosan (TMC)[102] and Poly(lactic-co-
glycolic acid) (PLGA) based particles [103]. Our model system is spherical in 
shape and made of polymerized polystyrene, similar to structures generated 
through conventional techniques of particle fabrication like emulsion, precipitation 
and polymerization of formulations. The application of ligand based targeting is 
currently largely employed in such platforms to attain specific attachment and 
receptor mediated endocytosis to diseased cells. The ligand functionalization 
provides better therapeutic performance especially for macromolecules that 
cannot easily enter cells on their own [102-104]. Such targeted platforms also 
expresses better uptake by cells based on vascular permeability [105], tumor 
penetrability [105] and ligand-receptor density and affinity [106-107]. The particle 
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sizes in our study roughly cover the size range of established delivery platforms 
[102-103, 108].  
Our work helps to determine the transport properties of drug carriers in the 
microvasculature. From this study we conclude that 2 µm particles have better 
binding efficiency based on number count and particle volume, for low to medium 
shear rate flow regions. For disease conditions where a higher particle 
concentration or dosage is acceptable (drug toxicity not an issue) and higher shear 
flows are involved, the smaller particles in the 200 nm scale would be more 
suitable. Properties like the enhanced particle margination and binding to the wall 
at high particle flow concentration observed in this study favour the use of NPs. 
Other advantages like the ability to be better retained in tissues via the enhanced 
permeability and retention effect, longer circulation period and better targeting 
ability are also in favour of NPs.  
When designing targeted vascular drug carriers, various parameters have to be 
considered like the disease condition, permissible drug toxicity based particle 
concentration, reticuloendothelial system evading properties etc. This work is part 
of a project to develop a customized biomimetic microfluidic experimental platform 
that mimics specific microvasculature conditions based on disease state and 
physiological conditions. These goals are to be achieved by coating the 
microfluidic channels with endothelial cells to mimic vascular morphology and to 
mimic disease condition by introducing specific cytokines. Thus a more 
physiologically relevant test condition can be set up for studying nano/micro drug 
carrier distribution and binding.  
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Chapter: 5 
Model 2: endothelial cell coated vascular morphology mimicking 
platform 
5.1 Introduction 
An endothelial cell coated blood vessel model on a microfluidic channel is the most 
fitting approach to prototype an in vivo blood vessel. Our model has been designed 
to mimic spatially controlled healthy and diseased vascular morphology regions in 
the same channel. This model will advance the understanding of mechanisms 
involved in drug carrier binding in a blood vessel at cellular level. It also examines 
the boundary effect on targeted binding in healthy vs. diseased sections of a blood 
vessel. 
The endothelial cell coated blood vessel model proposed here has a top and 
bottom chamber separated by a semi-permeable, porous, cell culture friendly 
membrane (Figure 15). Endothelial cells will be grown on the membrane such that 
the apical plane of the cell faces the top chamber and the basal plane the bottom 
chamber of the device. The upper and lower chambers are denoted as the apical 
side and the basal side respectively, corresponding to cell polarity. The chambers 
are designed such that a section of the apical side can be accessed from the basal 
side through the semi-permeable membrane. Endothelial cells growing on this 
section can be specifically simulated to be pathologically challenged through 
cytokine based activation from the basal chamber. This facilitates the simulation 
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of spatially controlled healthy and diseased endothelial cells in the same channel. 
Achieving a stable and confluent monolayer of endothelial cells, adapting them to 
physiological flow conditions and characterizing cell growth and cell parameters in 
this device form important steps in this study. Once these are established, 
microfluidic flow studies on drug carrier particle binding will be performed under 
physiologically relevant conditions.  
Primary BAOECs are used in this study and achieving a confluent monolayer of 
endothelial cells, adapting them to physiological flow conditions and establishing 
parameters for stable ICAM-1 expression form important steps in this study. We 
looked into the characteristics of endothelial cells cultured in our platform by 
studying the longevity of endothelial cells in these channels and investigating 
details on cell shape change and alignment by studying remodeling of actin 
microfilament network once exposed to FSS. Once the in vitro bio-mimetic blood 
vessel platform was established, flow studies on drug carrier particle binding were 
performed under physiologically relevant conditions. We characterized targeted 
nanodrug delivery in this more realistic blood vessel model and studied boundary 
effect of drug carrier binding in direct cytokine activated vs. non activated upstream 
and downstream vessel regions. This model will advance the understanding of 
mechanisms involved in drug carrier binding in a blood vessel at cellular level.  
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5.2 Materials and Methods 
5.2.1 Materials 
Human ICAM-1/CD54 MAb (Clone BBIG-I1) Mouse IgG1, ICAM-1/human IgG1 Fc 
chimera, biotinylated anti-human ICAM-1 (clone BBIG, mouse IgG1 κ) and Normal 
Goat IgG biotinylated control were purchased from R&D Systems, Minneapolis, 
MN). Protein G was bought from Biovision, Milpitas, CA. Horseradish peroxidase 
(HRP)-conjugated rat anti-mouse κ-light chain monoclonal antibody, neutrAvidin 
coated fluorescent yellow-green polystyrene 210 nm particles, Block-Aid, Amplex 
Ultra Red reagent and biotinylated-HRP were purchased from Invitrogen Carlsbad, 
CA. Mouse anti-human ICAM-1 monoclonal IgG1 antibody (clone 15.2)  was from 
Ancell, Bayport, MN and HRP-conjugated rat anti-mouse IgG1 monoclonal 
antibody from BD Biosciences San Jose, CA. Bovine serum albumin (BSA) and 3-
aminopropyltrimethoxysilane were bought from Sigma Aldrich, St Louis, MO. 
Streptavidin coated 2 µm fluorescent green polystyrene particles were purchased 
from Bangs Laboratories Inc., IN and polydimethylsiloxane  from Dow Corning, 
Midland MI.  
5.2.2 Fabrication of bio-mimetic blood vessel model 
Blood vessel mimicking channels are photolithographically fabricated on a silicon 
wafer and cast out of PDMS. The master for fabricating the channels is patterned 
on a silicon wafer using SU-8 2050 photoresist (MicroChem Corp.). Sylgard 184 
PDMS (Dow Corning Corp.) was prepared according to manufacturer's instruction 
and cast over the photoresist pattern. The upper channel is 350 µm wide and 100 
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µm tall, and the lower channel is 1000 µm wide and 100 µm tall. A polycarbonate 
(PC), track-etched thin clear membrane (Whatman, GE Healthcare) with 1 µm 
diameter pores and an average calculated pore density of 1.5*107 pores/cm2 is 
embedded between two PDMS channels. The process by which the device has 
been arranged has been detailed in other publications [109-111]. The PDMS slabs 
containing the top and bottom channels are carefully peeled off the master 
template. The property of PDMS is tuned to be more cell culture friendly by 
extended baking (4 hrs at 80oC) to ensure complete cross linking of monomers 
[112], and any leftover monomers are extracted by soaking them in ethanol 
overnight [113]. The bottom PDMS channel is kept thin to facilitate microscopy 
based imaging using higher magnification objectives. The bottom PDMS channel 
layer is bonded on to a thin glass slide by exposing the sides in contact to oxygen 
plasma. Upper and lower PDMS channels are bonded to the membrane by using 
a thin PDMS mortar film. The mortar film is a mixture of PDMS prepolymer (10:1 
ratio of base and curing agent) with toluene in equal proportion and a thin layer 
(~2-3 µm) is obtained by spin-coating this on a glass slide at 1500 rpm for 60 s. 
PDMS channel sides were stamped onto this thin film. Then the device is 
assembled with the membrane in between the PDMS slabs and making sure the 
channels are aligned. After assembly the device is placed in an oven at 60oC 
overnight for curing the PDMS mortar and ensuring the integrity of the device. Inlet 
and outlet ports were punched to provide access to top and bottom channels.  
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5.2.3 Endothelial cell culture in the device  
BAOECs were cultured in hepes buffered DMEM supplemented with 10% heat 
inactivated fetal bovine serum (Atlanta Biologicals, Inc.)  and 1% penicillin-
streptomycin (Sigma-Aldrich). The device was sterilized in UV light overnight. Prior 
to cell seeding the upper channel and membrane of the device was coated with 50 
µg/ml fibronectin solution (Sigma-Aldrich) overnight at 37oC. The channel was 
rinsed with media to remove any excess, unattached fibronectin. BAOECs  cells 
were seeded onto the semi-permeable membrane in the upper channel at a 
density of 2*107 cells/ml. Cell seeded devices were placed in an incubator under 
standard culture conditions (37oC and 5% CO2) overnight to allow cell attachment 
and spreading on the membrane. For the next 12 hrs the upper channel of the 
device was subjected to flow based media change at low FSS (0.01 dyne/cm2). 
Thus a constant supply of fresh media was available for the BAOECs without being 
subjected to FSS effects. Later the flow rate of media in the upper channel was 
gradually increased to subject the endothelial cells to physiologically relevant FSS 
values.  
5.2.4 Application of shear stress 
Quiescent phenotype of endothelial cells is critical to the success of our work and 
for this the confluent layer of BAOECs were subjected to physiologically relevant 
FSS. To calculate the volumetric flow rate that correspond to the required 
maximum FSS experienced by the endothelial cells, the following equation was 
used [114]. 
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&'()) =	 +,-./0   
On reaching confluence, the BAOECs were subjected to a FSS of 12 dyne/cm2. 
The flow was brought about using a high precision and extremely low pulsation 
peristaltic pump (ISMATendothelial cell, IPC-N series) and the entire setup was 
placed in standard culture conditions. The use of a peristaltic pump allows 
multiplex access to the flow channel, providing the flexibility of introducing new 
entities (particles, specific biomolecules etc.) without disturbing the laminar FSS 
the BAOECs are being exposed to.      
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5.3 Results and Discussion 
5.3.1 Design of microfluidic device 
 
   
Figure 15: A, Graphical schematic (left) and photograph (center) of the bi-layer device showing 
the upper (marked with yellow lines) and lower (marked with red lines) channel separated by 
the semi-permeable membrane. Schematic on the extreme right depict endothelial cell growth 
on semi-permeable membrane and TNF-α treatment from the lower channel.  B, (a) Bright field 
image of the top (marked with yellow lines)  and bottom (marked with red lines) channel 
defining the upstream, TNF-α activated and downstream sections, (b) Fluorescence labeled 
actin cytoskeleton (FITC phalloidin) images of confluent BAOEC layer aligned to flow (12 
dyne/cm2 FSS for 24 hrs). The cells grow on the semi-permeable membrane in the top channel 
of the device. Arrow shows flow direction (Scale bar: 100 µm) 
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The microfluidic device channels are made of PDMS and the upper channel is 20 
mm long and has a width of 350 µm. The lower channel is 5 mm long and 1 mm 
wide and is arranged perpendicular to the top channel (Figure 15 A). The top 
channel is bonded to the bottom channel with the semipermeable membrane in 
between through O2 plasma bonding and by applying liquid PDMS along the channel 
edges. The porous PC membrane is cell culture friendly and provides the base for 
cell growth and proliferation. Such membrane based mimicking of biological 
platforms has been widely demonstrated [110-111, 115-116]. Transport of 
materials between the upper and lower channels is limited to diffusion through the 
membrane pores. This allows for spatially controlled and independent transport 
between the channels without leakage. 
5.3.2 On-chip cell culture 
Endothelial cells are constantly exposed to blood flow as they form the 'tunica 
intima' or the inner coat of a blood vessel. The exposure of endothelial cells to this 
shear stress activates a number of cellular mechano-sensors, which along with 
adaptor molecules regulate the expression of genes and proteins relevant to 
endothelial cell functions in healthy and disease conditions [117-118]. Maintaining 
the quiescent phenotype of endothelial cells is critical to the success of a 
biomimetic blood vessel model and subjecting the endothelial cells to native in vivo 
FSS is important [119]. Pro-inflammatory and proliferative pathways of vascular 
endothelial cells become down-regulated when the endothelial cell layer is 
exposed to directed and sustained FSS [120]. To validate the bio-mimetic nature 
of our device, confluent layer of BAOECs were subjected to physiological levels of 
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FSS (12 dyne/cm2). BAEOCs were exposed to steady and directed laminar FSS 
for a time period of 5 days to check the longevity of maintaining a confluent cell 
layer. Confluent and flow aligned BAOEC layer after 5 days looked similar to the 
F-actin stained illustrative image of BAOECs at 12 dyne/cm2 FSS after 24 hrs in 
Figure 15 B (b), confirming the maintenance of a quiescent and sustaining 
phenotype by the BAOECs.  
5.3.3 Endothelial cell alignment and stress fiber arrangement under FSS 
To further examine the state of BAOECs under flow in our device, their actin 
assembly characteristics were studied. endothelial cells exposed to FSS undergo 
a change in cell shape and their microfilament network remodels and aligns to the 
direction of flow [121]. We examined this by staining F-actin stress fibers of 
BAOECs growing in the upper channel. The exposure of cells to flow at 12 
dyne/cm2 resulted in alteration of cell shape from the typical cobblestone pattern 
to fusiform as observed in endothelial cells in vivo [122-123]. The cells and their 
actin stress fibers were uniformly aligned in the direction of flow ( 
Figure 16B). The control (no flow) case had the F-actin fibers arranged in a radial 
pattern or emerging from the edges, a mechanism to maintain the cell well-spread 
( 
Figure 16A). To better depict the relationship between cell orientation and flow 
direction, the angle (α) between the orientation of stress fibers and the width (short-
axis) of the microchannel was plotted. It is observed that for the control case the  
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S'tress fibers align at an average angle of 51.4o, while the cells exposed to flow 
show an average angle of 90.1o ( 
Figure 16C). This result is consistent with previous studies [121, 124]. 
The thickness of the cortical actin and width of stress fibers were calculated from 
the fluorescence labeled actin cytoskeleton images. In BAOECs subjected to 12 
dyne/cm2 of FSS for 4 hrs, the thick cortical actin was found to reorganize into actin 
stress fibers along the direction of flow (Figure 17). About ~2 fold decrease in 
thickness of cortical actin is observed (Figure 17 A). The width of stress fibers 
increases ~2 fold as well for BAOECs subjected to FSS (Figure 17 B). Previous 
works have identified JNK activity-dependent cortical actin remodeling into stress 
fibers when exposed to flow, allowing the cells to maintain their mechanical 
integrity and cell-cell contact [125].  
 
         
Figure 16: Organization of F-actin stress fibers (green) in BAOECs assessed by 
confocal microscopy (A) Static case; Cell stress fibers tend to align parallel to the 
width of the channel. (B) After 4 hrs of flow at 12 dyne/cm2 FSS; Cell stress fibers 
tend to align parallel to the flow direction. Inserts show zoomed in images of stress 
fiber alignment. Arrow marks the flow direction. (C) Quantitative measurement of 
stress fiber alignment angle (α) to the width of the channel under static and flow 
shear stress case (*p<0.001, ** p<0.0001, *** p<0.00001, by Student's t test) 
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Figure 17: Reorganization of cortical actin into stress fibers in BAOECs 
subjected to FSS. Flow-induced actin remodeling was observed by fluorescence 
labeling of the actin cytoskeleton with FITC-conjugated phalloidin in BAOECs 
treated with 12 dyne/cm2 FSS for 4 hrs. Comparison of (A) Cortical actin 
thickness; (B) Stress fiber width; distribution in static and flow (12 dyne/cm2 FSS 
for 4 hrs) culture conditions. (*p<0.001, ** p<0.0001, *** p<0.00001, by 
Student's t test) 
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Figure 18: Comparison of stress fiber distribution in BAOECs subjected to FSS with no flow case. 
Actin stress fibers of BAOECs are labeled with FITC-conjugated phalloidin. (A), Fluorescence 
intensity (grayscale value) of stress fibers is quantified using ImageJ software across the marked line 
and corresponding line graphs are plotted for, (a,b) no flow (control) case; and (c,d) endothelial cells 
treated with 12 dyne/cm2 FSS  for 4 hrs.  (B), (a) Total number of fluorescence intensity (grayscale 
value) peaks of stress fibers in control and flow case; (b) Thin and thick actin stress fibers were 
marked by classifying stress fibers based on grayscale value ≤50 as thin and >50 as thick in the 
BAOECs for both control and FSS case. Arrow indicates flow direct. (Scale bar: 10 µm).  
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Since the actual aggregate of stress fibers cannot be understood from analyzing 
the width of the stress fibers alone (thickness of stress fibers in the z direction not 
considered), we quantified their fluorescence intensity in grayscale value and 
plotted the corresponding line graphs (Figure 18 A). This gives us an idea of stress 
fiber density present in the cell (Figure 18 B) as well. The exposure of endothelial 
cells to FSS organizes thick stress fibers along the direction of flow both in situ and 
in vitro [126]. We observe multiple but less intense stress fiber distribution across 
the cytoplasm of BAOECs for the no flow case based on fluorescence intensity 
[Figure 18 A, (a,b)]. BAOECs subjected to flow have fewer but more profound and 
sharp stress fiber distribution [Figure 18 A, (c,d)]. Stress fiber density in the cells 
was quantified by doing a line profile across the cytoplasm of BAOECs and using 
ImageJ software to calculate fluorescence intensity [127]. The software identifies 
stress fibers by their increased fluorescence relative to areas devoid of stress 
fibers. Sharp, distinct peaks represented individual stress fibers, while the width 
and fluorescence intensity of the peak indicated the thickness of a stress fiber 
[Figure 18 B, (a)]. Thin and thick actin stress fibers were quantified for both control 
and FSS cases by classifying stress fibers based on fluorescence intensity 
(grayscale value).  For statistical purposes, stress fibers with fluorescence intensity 
≤50 grayscale value were arbitrarily marked as thin and >50 as thick [Figure 18 B, 
(b)]. The no flow case has almost an equal distribution of thin and thick stress 
fibers, while the BAOECs subjected to FSS have a significant distribution of thick 
stress fibers in their cytoplasm. Laminar and sustained FSS induces thicker stress 
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fiber organization in endothelial cells along with the direction of flow along with 
maintaining elongated cell morphology.       
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5.4 Conclusion 
By smart integration of biology and engineering it was possible to design a 
biomimetic blood vessel environment that combines microenvironmental control 
with cell specific transport and signalling. Endothelial cells were cultured under in 
vivo levels of flow, a more realistic and accurate environment as an intact 
endothelium is exposed to constant blood flow. These cells had access to an 
uninterrupted nutrient supply and could be triggered with external cues from the 
apical or basal side. We established the longevity of maintenance of a uniform 
monolayer of endothelial cells when cultured under flow to a minimum of at least 
5 days. The F-actin stress fiber remodeling and arrangement pattern shift once 
subjected to FSS. There was a significant increase in the presence of stress fibers 
in the cell cytoplasm, oriented to the long axis of the cell and arranged parallel to 
each other once subjected to flow. The presence of cortical actin also diminished 
in the endothelial cells after exposing to FSS. This platform is to be used for 
characterizing the activation of endothelial microenvironment by studying the 
expression of surface ICAM-1 after local action of TNF-α, and also to study the 
dynamics of change in vascular permeability once triggered with thrombin, an 
acute blood vessel inflammatory mediator. These studies have been explained in 
the following chapters. 
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Chapter 6 
Dynamics of endothelial activation by local action of pro-
inflammatory cytokines  
6.1 Introduction 
The biological relevance of the conventional cell culture models is limited. Both 
understanding of pathophysiology and design of adequate interventions demand 
alternative bio-mimetic model platforms with intermediate ratios of 
feasibility/complexity, allowing researchers to more adequately address specific 
inquires in the relevant context. We are combining endothelial microfluidics/flow 
adaptation approach with local cytokine application via a permeable “sub-
endothelial compartment” and antibody-coated nanoparticles as imaging probes. 
This approach allowed us to define flow-mediated local heterogeneity of 
endothelial activation by cytokines that appears to reflect the pathophysiology of 
the process. Such pro-inflammatory processes are also symptomatic of enhanced 
endothelial permeability due to inter-cellular gap formation and this phenomenon 
has been characterized using fluorescent dye diffusion studies.  Furthermore, the 
results of this study support design of drug delivery systems employing affinity 
nanocarriers targeted to the pathological endothelium.   
Inflammatory conditions like rheumatoid arthritis, inflammatory bowel disease, 
asthma, chronic airway inflammation, atopic dermatitis, and psoriasis [20, 21]. as 
well as presence of foreign materials leads to the action of  several inflammatory 
mediators (e.g., Vascular endothelial growth factor- (VEGF)-A, Tumor necrosis 
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factor- (TNF)-α, Interleukin- (IL)-6, and IL-1β) on the blood vessel. This leads to an 
increase in vessel permeability and delivery of immunoglobulins, antiproteases, 
constituents of the complement and coagulation systems and other acute phase 
proteins to the site to act in local host defense and initiate tissue repair. 
Furthermore, the expression of adhesion molecules, such as intercellular adhesion 
molecule- (ICAM)-1, vascular cell adhesion molecule- (VCAM-)1, and E-selectin 
on activated blood vascular endothelial cells, induce neutrophil and monocyte 
infiltration which collectively increase the permeability of endothelial cell junctions 
[128-139]. Determining the underlying mechanism requires multidisciplinary 
approaches [140-141]. By understanding this we can engineer nanodrug carriers 
with optimized ligands and coating densities to facilitate trans-endothelial drug 
delivery with high efficacy at sites of inflammation [142].  
An in vitro bio-mimetic blood vessel should be able to model in vivo physiological 
characteristics like pathological microenvironment, relevant flow dynamics and 
vessel shape dimensions. Microfluidic engineering enables integration of precisely 
controlled flow in channels, whose shape and dimensions can be designed to 
requirement with resolution limits in the micron scale. In the previous section 
details about the fabrication of the biomimetic blood vessel system and the 
characterization of endothelial cell growth in this device were presented. In this 
chapter TNF-α mediated ICAM-1 expression was produced in the endothelial cells 
and anti-ICAM-1 coated 210 nm and 1 µm particles were used as imaging probes 
to characterize their presence under physiologically relevant conditions. Binding 
studies using ICAM-1 ab coated particles of different sizes and coating densities 
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under physiologically relevant flow conditions allowed investigation of spatial 
organization of ICAM-1 expression at different levels of detection sensitivity.  This 
approach allowed us to study the dynamics of flow-mediated heterogeneous 
expression of ICAM-1 in endothelial microenvironments when locally activated. F-
actin depolymerization and rearrangement were also found to occur in sections 
that were locally TNF-α triggered. The upregulated expression of surface ICAM-1 
is evident and steady in the locally TNF- α treated region, but decreases along the 
length of the channel in the downstream section to match with the basal expression 
levels observed in the upstream regions.  F-actin depolymerization and 
rearrangement also follows the same trend.  
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6.2 Methods 
6.2.1 TNF-α treatment 
BAOECs after being subjected to 24 hrs or more of flow at 12 dyne/cm2 were 
treated with TNF-α to locally activate ICAM-1 expression on the endothelial cell 
layer. This treatment was performed on an 80-90% confluent cell layer. BAOECs 
were locally activated by introducing DMEM media containing 10 Units (U)/ml of 
TNF-α for 2 hrs in the lower channel of the device. A time course study on TNF-α 
based expression of surface ICAM-1 by BAOECs was performed and 2 hrs of 
treatment was found to be optimal (Figure 20). TNF-α diffuses through the semi-
permeable pores of the membrane separating the lower from the upper channel 
and spatially controls the direct activation of BAOECs only present above the lower 
channel. BAOECs on the upstream or downstream sections of the upper channel 
with respect to the TNF-α treated region do not come in direct contact with the 
inflammatory cytokine. Here the BAOECs are cytokine treated form the basal side 
of the cell.  
6.2.2 Binding of anti-ICAM-1 coated particles on BAOEC layer 
A particle binding study was performed on TNF-α activated live BAOECs in a 
continuous manner by introducing particles at their respective concentrations for 
designated flow times (Table 4) without stopping the flow and while TNF-α 
activation of endothelial cells is still conducted from the lower channel. This keeps 
the targeted drug carrier binding study set-up as close to native, in vivo condition 
as possible and maintains a stable endothelial cell niche microenvironment.  
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Table 3: Final particle concentration (#/ml) for 210 nm and 1 µm particles. The total 
particle volume is constant for both particles 
                                                                                 
 
 
 
Table 4: FSS and corresponding volumetric flow rate values along with flow time 
for 6, 12 and 18 dyne/cm2 cases. Flow time decreases with FSS to maintain the 
'total number of particles/flow case' a constant      
          
 
The particle working concentrations for performing binding test of 210 nm and 1 
µm particles were chosen such that the total volume of particles remained a 
constant (Table 3). Also, in order to make sure the 'total number of particles/flow 
case' remains a constant for all particle binding FSS cases, the flow time 
decreased with an increase in FSS (Table 4). This maintains the total volume of 
particle solution in all cases the same.   
Flow shear 
stress 
(dyne/cm2) 
Flow rate in ml/hr (viscosity: 
0.007 dyne sec/cm2 for 
media) 
Flow time (minutes) for 
particle flow study in 
media/pure buffer 
6 1.8 6 
12 3.6 4 
18 5.4 2 
 
Particle 
size 
Final particle concentration Total particle volume (µm3) 
210 nm 4.77 * 109/ml 20000000 
1 micron 3.85 * 107/ml 20000000 
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The particles were infused into the upper channel of the device and after their 
designated flow time unbound particles were removed by flushing with a buffer 
solution. The wash buffer contains a plasma membrane stain (CellMask™, Life 
technologies) to fluorescently tag the BAOECs. The particle bound BAOECs are 
then fixed in paraformaldehyde (3.7%). Particle binding is analyzed by phase 
contrast and fluorescence microscopy (FV1000-IX81, Olympus) and image 
analysis was performed using ImageJ software. 
6.2.3 Preparation and characterization of anti-ICAM-1 coated particles 
Neutravidin coated 210 nm and 1 µm fluorescent particles (Invitrogen Corp.) were 
diluted to 1010 and 109 particles/ml respectively using BlockAid™ solution 
(Invitrogen Corp.) and sonicated. Biotinylated Protein G (29988, Thermo Scientific) 
diluted in 1% BSA solution was bound to the NeutrAvidin coating on the particles 
initially. This is followed by binding ICAM-1/Control IgG (or both) antibody (NB500-
318, Novus Biologicals) with specificity for bovine cells to the Protein G coated 
particles. The particles were incubated for 12 hrs on a shaker at 4oC for both 
coating steps and the unbound protein G/antibody was removed by centrifugation. 
The particles were also washed in 1% BSA solution to remove any leftover 
unbound protein G/antibody, and finally the particles were diluted to their 
respective working concentrations (Table 1). The concentration of the particles 
available was analyzed on a microplate reader at 485 nm excitation/530 nm 
emission and compared to a calibration curve constructed from stock particle 
solution.  
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The anti-ICAM-1 coating density on the particle was determined using ELISA. 210 
nm particles were conjugated with anti-ICAM-1 at 100% (possible maximum) and 
50% of coating density, while 1 µm particles only had the maximum antibody 
coating density case. ELISA was performed using an HRP conjugated anti-mouse 
k-light chain specific monoclonal antibody to characterize the particle surface 
antibody density for both micro/nano particles. The specificity of the reagent to 
mouse antibody light chains provides a direct measurement of the anti-ICAM-1 
binding sites available on the particle. Particles were incubated with 5% HRP 
conjugated anti-mouse k-light chain specific monoclonal antibody for 30 minutes, 
followed by washing with 1% BSA solution and clearing out of unbound antibody 
through centrifugation. 50 µl of the particle solution were loaded on a 96-well plate 
and the particle concentration was analyzed. Then 50 µL of Amplex Ultra Red 
reagent was added to each wells and the reaction was allowed to proceed for 10 
minutes at room temperature. The fluorescence intensity of the particle sample 
with Amplex Ultra Red reagent was observed on a microplate reader at 544 nm 
excitation/590 nm emission. The fluorescence intensities were converted to the 
number of HRP molecule using the calibration curves prepared using biotinylated-
HRP conjugation.  Assuming a 1:1 binding ratio between anti-ICAM-1 and 
secondary antibody, the anti-ICAM-1 density on the particles were determined. 210 
nm and 1 µm particle antibody coating density based on fluorescence intensity was 
compared to estimate the relative accuracy of the technique. 
Complete saturation of anti-ICAM-1 coating on 210 nm particles produced 232.5 ± 
25 anti-ICAM-1/particle and this was brought down to 112.9 ± 19 anti-ICAM-
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1/particle as well using control IgG antibody. These correspond to 1851.2 ± 
199/µm2 for the maximum antibody density case and 898.9 ± 151 anti-ICAM-1/µm2 
respectively. 1 µm particles have an antibody density of 2367.8 ± 264 anti-ICAM-
1/particle which corresponds to 232.9 ± 25 anti-ICAM-1/µm2.  
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6.3 Results and Discussion 
6.3.1 Targeted binding of anti-ICAM-1 coated particles on BAOEC layer 
 
 
 
 
 
 
Figure 19: Binding of Anti-ICAM-1/Control IgG coated 210 nm particles on 
BAOECs under flow. A, Fluorescence micrographs show binding of particles to 
TNF-α activated BAOECs under different conditions, (a) Anti-ICAM-1 coated 
particles with a density of ~1900/µm2 µm2 (~230 molecules/particle) at FSS of 6 
dyne/cm2; (b) Anti-ICAM-1 coated particles with a density of ~1000/µm2 (~110 
molecules/particle) at FSS of 6 dyne/cm2; (c) Control IgG coated particles at FSS 
of 6 dyne/cm2. (Scale bar: 20 µm). B, Quantification of anti-ICAM-1 and control IgG 
coated particle binding per cell at FSS of 6 dyne/cm2 on TNF-α activated BAOECs 
, (a) Anti-ICAM-1 coated particles with a density of ~1900/µm2 (~230 
molecules/particle) and Control IgG coated particles; (b) Anti-ICAM-1 coated 
particles with a density of ~1000/µm2 (~110 molecules/particle) and Control IgG 
coated particles. (*p<0.001, ** p<0.0001, *** p<0.00001, by Student's t test) 
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TNF-α activated BAOECs would have upregulated expression of ICAM-1 among 
other endothelial cell surface proteins [143]. A time course study on TNF-α based 
expression of surface ICAM-1 by BAOECs cultured in petri-dish showed 2 hrs of 
treatment to be optimal (Figure 20). The BAOECs are cytokine-treated from the 
basal side of the cell. To understand the difference in basal and apical cell side 
TNF-α treatment on surface ICAM-1 expression, BAOECs were subjected to these 
two cases separately. The cells expressed similar levels of ICAM-1 expression for 
both cases characterized by targeted particle binding (Figure 21). In our work, the 
ICAM-1 expression was evaluated by studying specific binding of anti-ICAM-1 
coated particles to endothelial cells in the upper channel. 210 nm nanoparticles 
coated with anti-ICAM-1 or control IgG were perfused at 6 dyne/cm2 FSS. Anti-
ICAM-1 coated NP bound to cytokine-activated endothelial cell specifically, 
exceeded binding of control IgG coated NP by ~20 times and ~50 times when 
coated by anti-ICAM at 112.9 ± 19 and 232.5 ± 25 antibody/particle, respectively 
(p<0.00001) (Figure 19). Anti-ICAM-1 coated NP binding to TNF-α treated 
endothelial cell was further enhanced in FSS-exposed compared to static 
endothelial cells, consistent with observations in other models [144] (Figure 19 vs. 
Figure 20) 
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6.3.2 Time course study on TNF-α based expression of surface ICAM-1 by 
BAOECs under static culture condition  
 
Figure 20: Binding of Anti-ICAM-1/Control IgG coated 210 nm particles on 
BAOECs cultured in a petri dish. A, Fluorescence micrographs show binding of 
particles to 2 hr TNF-α (10 U/ml) activated BAOECs, (a) Anti-ICAM-1 coated 
particles with a density 232.5 anti ICAM-1/particle; (b) Control IgG coated particles. 
(Scale bar: 20 µm). B, Quantification of anti-ICAM-1 and control IgG coated particle 
binding per cell on TNF-α activated and control BAOECs.  
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6.3.3 BAOECs treated with TNF-α from the basal and apical side of the cell 
 
 
 
Figure 21: Binding of anti-ICAM-1 coated  210 nm particles (232.5 anti ICAM-
1/particle) on BAOECs treated with TNF-α (10U/ml) from the basal and apical side 
of the cell, (A) Schematic illustrating the TNF-α treatment procedure; (B) Particle 
binding/cell quantification of anti-ICAM-1 coated 210 nm particles (232.5 anti 
ICAM-1/particle) on ICAM-1 expressing BAOECs. (n=100 cells from three 
independent experiment for each case) 
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6.3.4 Characterization of flow-mediated localized BAOEC activation using 
fluorescent probes  
     
Figure 22: Targeted binding of anti-ICAM-1 coated particles of different antibody 
coating density on BAOECs in the upstream, TNF-α treated and downstream 
sections of the channel at different shear rates. Quantification of particle binding 
density per cell at 6, 12 and 18 dyne/cm2 for 210 nm particles with A, anti-ICAM-1 
coating density of 232.5 ± 25 anti-ICAM-1/particle and B, anti-ICAM-1 coating 
density of 112.9 ± 19 anti-ICAM-1/particle. Data are shown as mean ± S.D. (n=50 
cells). p<0.01 by one way ANOVA test for particle binding data compared between 
upstream, TNF-α treated and downstream regions for both 232.5 ± 25 and 112.9 
± 19  anti-ICAM-1/particle cases.  
The design of our bio-mimetic blood vessel platform allows a section of the upper 
channel to be accessed independently. This facilitates spatially controlled cytokine 
activation of endothelial cells. Having both direct cytokine-activated and non-
activated endothelial cells in the same channel allowed investigation of the 
heterogeneous nature of ICAM-1 expression and the hemodynamic control of the 
marginal zone between inflammation foci and relatively normal vasculature. 
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antibody coating densities to ICAM-1 under physiologically relevant FSS 
characterizes the distribution and accessibility of ICAM-1 on endothelial cells. Such 
studies can shed light on parameters involved in receptor-ligand recognition for 
activated blood cells and affinity drug carriers.  
As the endothelial cells were fluorescently tagged, the boundaries of individual 
cells were marked and the number of particles binding per cell was counted using 
ImageJ software. The binding of fluorescent particles to ICAM-1 in the upstream, 
TNF-α treated and downstream areas of the channel was studied using antibody 
coated 210 nm and 1 µm particles. Flow rates of 6, 12 and 18 dyne/cm2 were 
employed after the BAOECs were treated with TNF-α for 2 hrs under a steady and 
sustained FSS of 12 dyne/cm2. 
BAOECs in the TNF-α treated section of the upper channel have around 4-5 times 
higher particle binding density compared to the upstream section for 210 nm 
particle with a coating density of 232.5 ± 25 anti-ICAM-1/particle (Figure 22 B) 
(p<0.01). A similar trend was observed for the lower antibody coating density case 
(Figure 22 A) and this was consistent for all the flow cases for both particle antibody 
coating densities. This clearly showed a significant increase in surface ICAM-1 
expression in BAOECs at the TNF-α treated section. The p value is <0.01 by one 
way ANOVA test for particle binding data compared between TNF-α treated, 
upstream and downstream regions for both 210 nm particle antibody coating 
density cases. The downstream section of the channel also showed significantly 
higher (around 2 times) particle binding density compared to the upstream section 
(p<0.01).  
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The particle binding density depends on the antibody coating density. When 
compared to the 232.5 ± 25 anti-ICAM-1/particle case, the particle binding density 
was around half for the 112.9 ± 19/ anti-ICAM-1 particle case. Previous studies 
have reported the binding kinetics of particles with higher anti-ICAM-1 coating 
density to be significantly faster [145-146]. This increased binding density of 
particles with higher antibody coating is consistent with other studies and our 
previous work [68, 145]. The particle binding density decreased when the FSS 
increased from 6 to 12 dyne/cm2 for both anti-ICAM-1 coating density cases. An 
increase in FSS reduced the available time for particles to diffuse/marginate 
towards the endothelial cell surface, which reduced their binding density [145]. The 
particle binding density also doesn't reduce for FSS > 12 dyne/cm2 (Figure 22). 
Similar behavior has been reported in previous studies where it is observed that 
flow can't generate enough drag force on the particle to significantly reduce the 
particle binding density after a critical shear rate [145]. Here the receptor-ligand 
bond strength between the 210 nm particle and the ICAM-1 molecules expressed 
on the endothelial layer should be higher than the drag force produced by the FSS 
on the nanometer scale particle (drag force generated is proportional to the size of 
the particle).  
Binding of anti-ICAM-1 coated 1 µm particles was also studied, but no significant 
binding was observed in any sections of the channel for a FSS range of 6-18 
dyne/cm2. Particle binding characteristics similar to that of 210 nm ones were 
observed when the FSS was brought down to 1.5 dyne/cm2 (Figure 24). Drag force 
generated on the bigger 1 µm particle is higher, making them easily detachable. In 
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addition, the role of accessibility and surface congruency of ICAM-1 is more limiting 
for large vs small ligand-coated particles.   
6.3.5 ICAM-1 and F-actin distribution pattern along the channel length 
In order to study the transition in ICAM-1 expression in the different sections 
(upstream, TNF-α treated and downstream) of the channel, we divided these 
sections into smaller segments and inspected the particle binding per cell along 
the length of the channel (Figure 23 B). An increase in particle binding density as 
a result of ICAM-1 expression by BAOECs was first observed in the upstream 
section of the channel very close to the TNF-α treated section (red lines mark the 
boundary in Figure 23A and B). Elevated particle binding density was observed all 
along the 1 mm long TNF-α treated section and extended into the nearby 
downstream regions. Particle binding density in the downstream section was 
significantly higher than that of the upstream section even though both sections 
were not TNF-α treated directly. There was a smooth decrease in particle binding 
along the channel length in the downstream section and after a channel length of 
about 3 mm the particle binding density became comparable to that of the 
upstream region. TNF-α treatment leads to cell-cell barrier dysfunction and 
intercellular gap formation in endothelial cells, thus increasing blood vessel 
permeability [147-149]. The increase in particle binding in the upstream section 
close to the TNF-α treated section and along the length of the downstream section 
could be due to a synergistic influence of flow and TNF-α diffusion through the 
BAOEC layer which has increased permeability in the TNF-α treated region. Flow 
directed from the TNF-α treated to the downstream section carried a majority of 
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the diffused TNF-α molecules towards the downstream section. The exposure to 
TNF-α led to upregulation of ICAM-1 expression on BAOECs here, which decayed 
along the channel length as the distance from direct TNF-α exposure increased 
and endothelial cells in its path bound remaining TNF-α.            
 
 
 
 
 
Inflammatory conditions lead to rearrangement of the actin cytoskeleton at 
endothelial cell junctions, regulation of endothelial permeability and barrier 
modulation [150-153]. We looked into F-actin stress fiber arrangement after TNF-
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Figure 23: Analysis of particle binding and F-actin stress fiber arrangement along 
the length of the channel after TNF-α treatment. A, Particle binding per cell at 6 
dyne/cm2 FSS along the length of the channel divided into upstream, TNF-α treated 
and downstream sections. Data are shown as mean ± S.D. B, F-actin stained 
image of BAOECs aligned to FSS at 12 dyne/cm2 for 4 hrs and TNF-α treated  for 
2 hrs at 10 U/ml. Zoomed in images (corresponding to dashed boxes) give better 
understanding of F-actin arrangement. Yellow bordered image represents control 
BAOECs flow aligned to12 dyne/cm2 FSS. Dashed boxes and magnified images 
are arranged in the same order. Arrow indicates flow direction. (Scale bar: 100 µm)
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α treatment along the channel length to further understand the endothelial cell 
microenvironment (Figure 23 B). A confluent BAOEC layer was exposed to 4 hrs 
of FSS at 12 dyne/cm2, which was followed by 2 hrs of localized TNF-α treatment 
(10 U/ml) from the lower channel. The cells were stained for F-actin stress fibers 
and their arrangement was studied in the upstream, TNF-α treated and 
downstream sections. BAOECs exposed to FSS in the upstream section had 
stress fibers aligned to flow direction (yellow bordered image in Figure 23 B). After 
2 hr exposure to TNF-α, there was a thinning of stress fiber filaments in the central 
area of the cell cytoplasm. This thinning started around the border of upstream and 
TNF-α treated sections. It was consistently observed all throughout the TNF-α 
treated section and continued towards the downstream section. The F-actin stress 
fiber thickness in the cell center increased smoothly to levels comparable to the 
upstream section after about 1 mm length in the downstream section. The thinning 
in F-actin fibers was likely due to TNF-α induced  F-actin remodeling observed in 
endothelial cells [147]. Rearrangement in F-actin stress fibers is also observed in 
BAOECs after TNF-α treatment. These isolated disruptions of the F-actin lattice 
were sparsely observed in the upstream regions close to TNF-α treated section, 
while they were more common in the TNF-α treated section. This was observed in 
the downstream section as well but the frequency of occurrence decreased along 
the channel length. This rearrangement of F-actin is a good indicator of barrier 
dysfunction and intercellular gap formation as a result of TNF-α treatment [147-
149], which is consistent with our assumption of TNF-α diffusion to the upper 
channel from the lower channel.    
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6.3.6 Targeted binding of anti-ICAM-1 coated particles of 1 micron size on flow 
aligned BAOECs  
 
 
 
Figure 24: Targeted binding of anti-ICAM-1 coated particles of 1 micron size on 
flow aligned BAOECs in the upstream, TNF-α treated and downstream sections of 
the channel at 1.5 dyne/cm2. A, Fluorescence micrographs show binding of 
particles on TNF-α activated BAOECs. B, Quantification of particle binding density 
per area at 1.5 dyne/cm2 for 1 µm particles with  anti-ICAM-1 coating density of 
~1500/µm2  
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6.3.7 Dynamic nature of surface ICAM-1 expression by endothelial cells 
The biomimetic blood vessel microfluidic model has a closed design and this 
allows the maintenance of cell culture friendly conditions inside the channel to 
sustain cell growth outside an incubator. By mounting the required experimental 
set-up on a microscope table (Figure 25 A), real time in situ studies can be 
performed on our blood vessel model. We applied this to study the dynamics of 
endothelial surface ICAM-1 expression induced by flow mediated TNF-α 
activation. The dynamics were characterized by studying the specific binding of 
anti-ICAM-1 coated 210 nm fluorescent particles (232.5 ± 25 anti-ICAM-1/particle) 
on BAOECs activated locally with TNF-α. The device with a monolayer of flow 
aligned endothelial cells in the upper channel was mounted on the microscope 
table and subjected to a FSS of 12 dyne/cm2 for 6 hrs before being locally TNF-α 
treated from the lower channel for 4 hrs. Anti-ICAM-1 coated particles were 
introduced to the flow and images were taken every 20 minutes to analyze the 
increase in particle binding on cell surface. The particle binding density per cell 
increased corresponding to an upregulation of ICAM-1 expression by BAOECs. 
This study provides a better understanding of the dynamics of ICAM-1 upregulation 
by BAOECs over time. Unlike that observed in static petri-dish studies where the 
ICAM-1 upregulation peaked after 2 hrs (Figure 20), this in situ observation under 
FSS showed a linear increase in ICAM-1 upregulation which peaked after 3 hrs 
and 20 minutes (Figure 25 C). The increased ICAM-1 expression in this case was 
a combined effect of flow and cytokine activation, as one could expect in vivo. This 
study provides a better understanding of the transient nature of ICAM-1 receptor 
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Figure 25: (A) Illustration of the real time particle binding study system on live 
cells. 210 nm particle binding per cell data over time to characterize surface ICAM-
1expression by BAOECs. (B) Images of 210 nm (green fluorescence) particle 
binding over stained (red) cells for different time points; (C) Particle binding per 
cell data for BAOECs before and after TNF-α over time. 
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6.4 Conclusion 
The biomimetic blood vessel model in this study is a tool with unprecedented ability 
to investigate the microenvironment of endothelial cells. The microfluidic chip can 
mimic a close to native environment for endothelial cells by facilitating in vivo levels 
of flow and biomolecule supply, along with an opening for localized access. We 
characterized BAOEC culture under physiological levels of flow and analyzed their 
F-actin organization pattern. Localized TNF-α treatment was performed on the 
BAOECs from the lower channel and ICAM-1 upregulation in the upstream, TNF-
α treated and downstream section of the channels was analyzed. We utilized this 
platform to perform targeted drug delivery by characterizing particle binding per 
cell for a FSS range of 6-18 dyne/cm2 using 210 nm particles. The novelty of this 
device revealed that BAOECs in the downstream section of a channel express 
higher ICAM-1 compared to the upstream section. By analyzing the particle binding 
along the length of the channel we characterized the nature of upregulation and 
fall in ICAM-1 expression for BAOECs from the upstream to TNF-α treated and 
downstream channel sections. We also outlined the nature of TNF-α based actin 
depolymerization and rearrangement along channel length. This work highlights 
the versatile nature and functionality of the microfluidic  
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Chapter 7 
Characterizing vascular permeability using a biomimetic 
microfluidic blood vessel model  
7.1 Introduction 
7.1.1 Vascular permeability and pathological significance 
Blood vessels are permeable, which allows for transportation of small molecules 
such as water, ions, nutrients, even a whole cell across vessels. This capability is 
called vessel permeability [154]. Endothelial cells line the blood vessel lumen and 
form a semi-permeable barrier through cell-cell conjunction. This basal level 
vascular permeability is essential in the selective transport between blood and the 
interstitial space of all organs. Such permeability barrier is maintained through tight 
cell-cell junctions and is controlled by growth factors, cytokines and other stress 
related molecules [155]. Disruptions in the endothelial cell layer barrier can result 
in increased permeability. The permeability of blood vessels increase on detection 
of a potentially harmful substance, foreign organism, or injured tissue cells, to 
supply plasma proteins to the extravascular compartment in need of repair. This is 
mediated by several inflammatory mediators (e.g., Vascular endothelial growth 
factor- (VEGF)-A, TNF-α, Interleukin- (IL)-6, IL-1β and thrombin delivers 
immunoglobulins, antiproteases, constituents of the complement and coagulation 
systems and other acute phase proteins to the site to act in local host defense and 
initiate tissue repair. Furthermore, the expression of adhesion molecules such as 
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ICAM-1, vascular cell adhesion molecule- (VCAM-)1, and E-selectin on activated 
blood vascular endothelial cells, induce neutrophil and monocyte infiltration which 
collectively increase the permeability of endothelial cell junctions [128-139]. These 
effects are observed as part of various disease states, and the understanding of 
the underlying mechanism requires multidisciplinary approaches [140-141]. 
Characterizing permeability of the endothelial cells that form the inner layer of 
blood vessels provides fundamental physiological information and is essential for 
evaluating drug and other biomolecule uptake. By understanding this we can 
engineer nanodrug carriers with optimized ligands and coating densities to 
facilitate trans-endothelial drug delivery with high efficacy at sites of inflammation 
[142].  
7.1.2 Associated diseases 
Vascular disruption and vessel leak is a common feature of acute and chronic 
injury and diseases such as atherosclerosis. Increased arterial endothelial cell 
permeability is considered an initial step in atherosclerosis [156-157]. In fact, 
atherosclerosis shows heterogeneous spotty leaky sites along healthy vessel 
[158]. During tumor growth, some unique pathophysiological characteristics that 
are not observed in normal tissues or organs are present, such as extensive 
angiogenesis and hence hypervasculature, defective vascular architecture, 
impaired lymphatic drainage/recovery system, and greatly increased production of 
a number of permeability mediators. This leads to higher pressure inside tumors. 
While the interstitial fluid pressure (IFP) in normal tissues is actively controlled and 
remains close to atmospheric levels, IFP in most human tumors is highly 
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elevated [159]. Getting chemotherapy agents into solid tumors can be a challenge 
because of high fluid pressure. Various other disease conditions also exhibit 
inflammation and increased vascular permeability as symptoms. In diabetes, 
hypoxic environment upregulated VEGF expression induces further elevated 
vascular permeability. Increased permeability of fluid and protein can lead to 
diabetic macular edema [160]. Other inflammatory conditions like rheumatoid 
arthritis, inflammatory bowel disease, asthma, chronic airway inflammation, atopic 
dermatitis, and psoriasis are also characterized by similar signs of inflammation 
[20, 21].  A better understanding of the dynamic nature of increase in vascular 
permeability and the peptide moieties involved can improve the ability to 
specifically target these sites to deliver drugs.   
7.1.3 Dynamic nature of vessel permeability 
Vascular permeability is a dynamic process. The processes are mediated by acute 
or chronic exposure to vascular permeabilizing agents, particularly vascular 
permeability factor/ VEGF, VEGF-A [161]. Experimental work has demonstrated 
that there are three patterns of increased leakage of fluid from vessels on three 
different times after injury. After endothelium exposure to histamine or thrombin a 
transient immediate and acute response can last for 30-60 minutes. A second 
response would happen 2-3 h after injury and lasts for up to 8 h. Local cells 
synthesize prostaglandins and platelet activating factors and mediate this 
response. If there has been some direct necrosis of the endothelium, a prolonged 
immediate response would occur over 24 h. In natural diseases all three responses 
may be activated, and sometimes an overlap of the three processes happens if 
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active inflammation is sustained [162-164]. Vascular permeability has also been 
found to be influenced by numerous (at least 25) gene products [161]. The dynamic 
nature of vascular permeability and the environmental factors involved are still 
elusive. 
 
 
7.1.4 Current in vivo and in vitro platforms  
The complex cellular mechanisms contributing to an increase in the permeability 
of blood vessels are partially understood. Scientists have employed in vivo and in 
vitro platforms to understand the underlying mechanism. Miles assay and its 
variants are established techniques to analyze vascular permeability in vivo [165-
168], as shown in Figure 27 (A-C). This assay determines the leakage of a visible 
dye from the vasculature into the surrounding tissue spectrophotometrically but 
has several limitations including that it only allows a single time point analysis, a 
high degree of variability and low repeatability, and an inability to investigate 
Figure 26: Schematic describing transport of molecules through the cardiovascular 
and lymphatic system in normal tissue with basal blood vessel permeability  and 
tumor or other inflammatory tissues with increased blood vessel permeability. 
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localized differences in vascular permeability [161, 169]. In vivo studies also often 
require complex mammalian models and time-consuming surgical protocols, 
making animals an expensive and challenging platform. They also raise ethical 
issues and such models also respond differently than humans as interspecies 
predictability is low in response to drugs and diseases [13]. In vivo studies also 
allow limited control of the heterogeneous physical, chemical, and biological 
parameters influencing the blood vessel and present challenges with respect to 
imaging as well [14].  
Relatively easier and simple in vitro platforms are also being used to better 
understand the phenomenon behind leaky and heterogeneous vasculature by 
measuring the flux of molecules of various sizes that traverse endothelial cells 
cultured in transwell chambers [170-174], as shown in Figure 27  (D-E). To 
measure the permeability of the cultured endothelial cell monolayer in vitro, 
conventional assays such as trans-endothelial electrical resistance(TEER) [175-
176] and tracer leakage [177-178] are widely used. TEER based assays are based 
on electrical impedance measurements which do not provide direct quantitative 
measurement of biomolecule transportation. In vitro studies are also mostly 
performed under static conditions without consideration of the FSS conditions the 
endothelium are exposed to in vivo. Kim et al [179] studies cytokine mediated 
controlled permeability on an endothelial cell layer through NP extravasation in a 
microfluidic platform. However, this study was performed under static condition 
without consideration of the FSS conditions the endothelium is exposed to in vivo. 
A few studies do incorporate FSS in the study of endothelial cell permeability [180-
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B
B
181]. An in vitro blood vessel model that incorporates endothelial cell culture under 
native conditions with the capability to model specific disease and physiological 
flow conditions has huge potential. Such a biomimetic system can greatly 
accelerate drug screening process in pharmacological studies. 
Figure 27: In vivo (A,B & C) and in vitro (D & E) techniques to analyze vascular 
permeability. A, Tumor vessel (red) showing localized leaky spots (green) [182];B, 
Fluorescent dye highlights intact blood vessel with basal permeability (Left). Tumor 
blood vessel with increased vascular permeability (Right)[183];C, Normal mouse 
retina. Right image (Left). Abnormal blood vessel growth and permeability 
characteristic of diabetes and inflammatory signaling [184-186]; D, Commercial in 
vitro vascular permeability test platform based on transwell inserts [187]; E, Bi-
directional transport studies using Caco-2 cells on transwell insert [188].   
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7.1.5 Significance of FSS 
Blood vessel endothelium is constantly exposed to FSS at its apical side due to 
blood flow. Maintaining the natural phenotype of endothelial cells is critical to the 
success of a biomimetic blood vessel model and subjecting the endothelial cells to 
native in vivo FSS is important [119]. Exposing the endothelial cell layer to directed 
and sustained FSS at in vivo levels down regulates their pro-inflammatory and 
proliferative pathways [120] and is critical to the expression of endothelial cell 
responses [189]. The mechanical stress caused on the endothelial cell layer due 
to this is an important extrinsic factor capable of modifying vessel barrier properties 
by altering the inter-endothelial junctions and the endothelial cell-extracellular 
matrix interactions [190-193]. It can also activate intracellular signaling events 
altering barrier properties like, increased intracellular Ca2+ levels and the 
generation of inositol trisphosphate [194-196], activation of Rac [197-198], RhoA-
dependent reorganization of actin cytoskeleton [191-192, 199] and β1-integrin-
dependent increase in caveolin-1 phosphorylation [191]. Therefore integrating in 
vivo levels of flow to the endothelial cell culture is important in limiting the chances 
of the cell monolayer undergoing phenotype drift and no longer reflecting its in situ 
characteristics. An in vitro blood vessel model that can sustain endothelial cell 
culture under native conditions, and is capable of evaluating the heterogeneous 
nature of vessel permeability when triggered by a single or a cocktail of 
inflammatory mediators holds huge potential. Such a translatory platform can 
bridge the gap between in vivo and traditional in vitro systems.  
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7.1.6 Thrombin 
Thrombin, a protease produced on the surface of injured endothelium from 
prothrombin can induce profound alterations of endothelial cell monolayer 
permeability in vitro and in vivo [200]. Thrombin induces blood coagulation, as well 
as also triggers specific stimuli on the endothelial cell layer leading to paracellular 
gap formation and release of inflammatory mediators, vasoregulatory agents, and 
growth factors. Paracellular gap formation of the endothelium is accompanied by 
reversible cell rounding and compromised barrier function [201]. Barrier integrity 
of the endothelium is ensured by the cytoskeleton, which is regulated by actin 
stress fiber formation and via actomyosin-driven contraction to managing cell 
shape and attachment [202]. Actin filaments at the periphery of endothelial cells 
are linked to cell-to-cell adherence junctions. These organelles are formed by 
transmembrane calcium-dependent adhesive proteins called vascular endothelial 
cadherins. These molecules are associated inside the cells with a complex network 
of cytoskeletal molecules [203-205].  
Proteinase-activated receptor (PAR) is the thrombin endothelial cell receptor 
protein and is similar to G-protein-coupled receptors containing seven 
transmembrane domains in its structure [206]. Binding of thrombin to PAR initiates 
activation of heterotrimeric G-proteins. This in turn produces a decrease in cyclic 
adenosine monophosphate level, increases intracellular Ca2+ and diacylglycerol 
concentration and activates the small G-protein, Rho, in the cell. Also, activation 
of myosin light chain kinase and inactivation of myosin phosphatases leads to 
phosphorylation of myosin light chains which stimulates stress fiber formation and 
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triggers actin-myosin contraction. In addition, Ca2+/calmodulin-dependent protein 
kinase, protein kinase C, and tyrosine protein kinases  regulate thrombin-induced 
rearrangement in the endothelial cytoskeleton [202]. These processes would 
sequentially lead to stimulation of an endothelial contractile reaction, which would 
eventually produce intercellular gaps.  
This project studies the dynamics of acute increase in endothelial cell permeability 
brought about by thrombin, an inflammation triggering agent in blood vessels. 
Thrombin induces blood coagulation and triggers specific stimuli on the endothelial 
cell layer leading to paracellular gap formation and release of inflammatory 
mediators, vasoregulatory agents, and growth factors [200]. The in vitro bio-
mimetic blood vessel platform used in this study consists of an upper and lower 
microfluidic channel separated by a semi-permeable membrane. Primary bovine 
aortic endothelial cells were cultured on the semi-permeable membrane under in 
vivo levels of flow. In order to study the increase in vascular permeability under 
inflammation, this monolayer of endothelial cells was exposed to flow of media 
spiked with thrombin and a tracer molecule. Efflux of fluorescein isothiocyanate 
(FITC)-dye and FITC-dextran tracer molecules were used to quantify the vascular 
permeability. The tracer molecule samples that permeated to the lower channel 
from the upper channel separated by the cell layer and membrane were collected 
real time and analysed to understand the dynamic nature of the process. The 
remodeling of F-actin stress fibers in endothelial cells on thrombin treatment was 
studied using immunofluorescence staining. This versatile platform facilitated the 
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study of the combined interplay of heterogeneous mechanisms contributing to an 
increase in permeability of blood vasculature. 
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7.2 Material and Methods 
7.2.1 Fabrication and endothelial cell culture  
Channels made of polydimethylsiloxane (PDMS) were photolithographically 
patterned and fabricated, and a monolayer culture of BAOECs was attained as 
explained in chapter # 5 and previous works [207]. The upper and lower channels 
are casted out of Sylgard 184 PDMS (Dow Corning Corp.). The upper channel is 
20 mm long, 350 µm wide and 100 µm tall, and the lower channel is 5 mm long, 
1000 µm wide and 100 µm tall. A polycarbonate (PC), track-etched thin clear 
membrane (Whatman, GE Healthcare) with 1 µm diameter pores and an average 
calculated pore density of 1.5*107 pores/cm2 is embedded between two PDMS 
channels. The bottom channel PDMS layer is bonded on to a thin glass slide by 
exposing the sides in contact to oxygen plasma. Upper PDMS channels is bonded 
to the membrane by using a thin PDMS mortar film (10:1 ratio of base and curing 
agent with toluene in equal proportion). The upper channel bonded to the 
membrane is then bonded to lower channel after making sure the channels are 
aligned. After each step the components were placed in an oven at 60oC for the 
appropriate time to enhance bonding. Inlet and outlet ports were punched to 
provide access to upper and lower channels.  
Once fabricated, the devices were sterilized in UV light overnight and certified for 
cell culture. Prior to cell seeding the upper channel and membrane of the device 
were coated with 50 µg/ml fibronectin solution (Sigma-Aldrich) overnight at 37oC. 
BAOECs cells were seeded in the upper channel at a density of 2*107 cells/ml and 
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let to attach on the semi-permeable membrane. Cell seeded devices were placed 
in an incubator under standard culture conditions (37oC and 5% CO2) overnight to 
allow cell attachment and spreading on the membrane. On reaching confluence, 
the BAOECs were subjected to a physiologically relevant fluid shear stress (FSS) 
of 12 dyne/cm2. The flow was brought about using a high precision and 
extremely low pulsation peristaltic pump (ISMATendothelial cell, IPC-N series) and 
the entire setup was placed in standard culture conditions. Recirculation of media 
was not permitted while thrombin and tracer molecules were passed through the 
channels. To calculate the volumetric flow rate that correspond to the required 
maximum FSS experienced by the endothelial cells, the following equation was 
used [114]. 
&'()) =	 +,-./0   
7.2.2 Thrombin treatment and cell permeability assay 
BAOECs were treated with thrombin at 1 Unit (U)/ml concentration after being 
subjected to 6 hrs or more of flow in the microfluidic model. Thrombin induces an 
acute inflammatory response on endothelial cells and leads to profound increase 
in endothelial cell monolayer permeability. Thrombin was added to flow media 
along with the tracer molecule and the treatment was performed under flow on the 
apical side of the cells. The dosage and treatment time for thrombin to induce an 
increase in permeability on BAOEC monolayer was determined from other studies 
[208-211] and by performing cell permeability assay on transwell inserts. For this 
the BAOECs were seeded at a density of 2 × 104 cells in the luminal chamber of 
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ThinCert transparent insert for 12-well plates having a membrane with 1 µm pore 
diameter. Cells were cultured in DMEM with 10% of heat inactivated fetal bovine 
serum and, upon confluence the cells were treated with thrombin by replacing the 
medium in the luminal side with fresh DMEM (1% heat inactivated serum) 
supplemented with thrombin and tracer molecule. Media volumes of 1500 µl and 
500 µl were maintained in the abluminal and luminal sides respectively to make 
sure the hydrostatic pressure between the chambers remained a constant. 750 µl 
of media from the abluminal chamber was replaced every 10 min and the presence 
of tracer molecule was monitored photometrically on the collected sample. To keep 
the permeability assay protocol in the biomimetic platform and the transwell insert 
study similar, the supplemented media in the luminal chamber was also replaced 
every 10 min to ensure a fresh and constant supply of thrombin and the tracer 
molecule. 
7.2.3 Quantifying vascular permeability 
Vascular permeability occurs through intercellular gap formation. We quantified the 
dynamics and kinetcs of cell permeability caused by thrombin on BAOECs using 
our biomimetic blood vessel model. Fluorescent FITC sodium salt and FITC-
Dextran (Sigma) of 376 and 4000 Da molecular weight were used as tracer 
molecules at 0.625 and 5 mg/ml respectively. The desired tracer molecule was 
included in flow media along with thrombin in the luminal upper channel and the 
extent of tracer molecule permeation to the abluminal lower channel is a direct 
indication of the level of vessel permeability. This was monitored real time by 
withdrawing 6 µl samples from the outlet of the lower channel every 10 minutes. 
112 
 
These samples were analyzed photometrically using Infinite 200 PRO NanoQuant 
microplate readers at 490 nm excitation and 521 nm emission. The volume of 
buffer solution in the lower channel was maintained constant by adding 6 µl of PBS 
to the inlet before withdrawing the data sample. The abluminal media sample 
collected every 10 min for the transwell insert static cell case was also analyzed 
as described above.  
7.2.4 Localization of Actin Filaments and Immunofluorescence Staining 
In order to understand the corelation between the increase in vessel permeability 
and F-actin cytoskeletal arrangement patterns on thrombin treatment, the 
rearrangement of F-actin stress fibers was studied. Confluent monolayers were 
treated with 1 U/ml thrombin in DMEM medium (1% heat inactivated serum) for 
various lengths of time. The static case was performed on endothelial cells cultured 
on fibronectin coated cover slips, and for the flow case thrombin was spiked along 
with flow media in the biomimetic microfluidic blood vessel platform.  After thrombin 
treatment, cells were fixed with 3.7% paraformaldehyde (Sigma) for 20 minutes 
and permeabilized with 0.5% Triton X-100 (Sigma) for 3 minutes. Endothelial cells 
were washed with PBS between each step and were finally stained with 50 µg/ml 
FITC-phalloidin (Thermo Fisher Scientific Inc.) solution in PBS and processed for 
immunofluorescence microscopy. Observations were performed with a 
fluorescence confocal microscope (FV1000-IX81, Olympus) and image analysis 
was performed using ImageJ software. 
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7.2.5 Statistical analysis 
The results are an average from three independent experiments with a p-value 
<0.05. The results are presented as the mean ± the standard deviation. An 
unpaired Student t test was used to analyze statistical differences between control 
and treated groups. Differences were considered statistically significant at p < 
0.05. 
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7.3 Results and Discussion 
7.3.1 On-chip cell culture 
Figure 28: (A) Photograph of the bi-layer device showing the upper and lower 
channel separated by the semi-permeable membrane along with their inlets and 
outlets. The apical side of the endothelial cell layer face the upper channel are 
exposed to media flow. Thrombin and tracer molecule are added to media to study 
blood vessel permeability under acute inflammation. Tracer molecule diffusion to 
the lower channel is controlled by the extend of endothelial cell permeability under 
inflammation. The diffused data sample is collected from the lower channel. (B) 
Bright field image of the membrane with 1 µm diameter pores at an average density 
of 1.5*107/cm2. (C) Schematic depiction of endothelial cell growth on semi-
permeable membrane, thrombin treatment from upper channel and tracer 
molecule diffusion through intercellular gaps. (D) Fluorescence labelled actin 
cytoskeleton (FITC-phalloidin) images of confluent BAOEC layer aligned to flow 
(12 dyne/cm2 FSS for 6 hrs) in the upper channel. Arrow shows flow direction 
(Scale bar: 100 µm) 
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Characterization of endothelial cell culture on the biomimetic blood vessel 
microfluidic device has been detailed in our prior work [207]. The device has the 
upper channel arranged perpendicular to the lower channel, and the media, 
thrombin and tracer molecule are flowed in through the inlet of the upper channel 
(Figure 28 A). The porous PC membrane is cell culture friendly and provides the 
base for cell growth and proliferation as demonstrated before [110-111, 115-116, 
207]. Transport between the upper and lower channels is limited through the 
membrane pores present at an average density of 1.5*107/cm2. This high pore 
density and the 1 µm pore diameter (Figure 28B) allow for free flow of tracer 
molecules through the membrane to the lower channel once it passes through the 
endothelial cell layer. As explained in Figure 28C, thrombin and tracer molecule 
flow along with media and thus thrombin would act on the endothelial cell from the 
apical side. With the onset of endothelial cell gap formation the tracer molecule 
would permeate through these gaps to the lower channel. Thus the extent of vessel 
permeability can be understood from the amount of tracer molecule in the lower 
channel.  
An intact blood vessel endothelium is constantly exposed to FSS at its apical side 
due to blood flow. Therefore integrating in vivo levels of flow to the endothelial cell 
culture is important in limiting the chances of the cell monolayer undergoing 
phenotype drift and thus no longer reflecting in situ characteristics. Figure 28D is 
a micrograph of F-actin stained confluent BAOEC monolayer aligned to flow (12 
dyne/cm2 FSS for 6 hrs) in our blood vessel model. Details on cell shape, F-actin 
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filament alignment and reorganization on exposure to FSS in this device have been 
reported previously in chapter 5 here.  
7.3.2 Characterizing vascular permeability on biomimetic blood vessel model 
Our platform is utilized to understand the increase in vessel permeability during an 
inflammatory state under physiologically relevant conditions. We used fluorescent 
tracer molecules of two different molecular weights and analyzed their diffusive 
permeability from the upper to the lower channel of the device, separated by the 
endothelial cell monolayer. The amount of tracer molecule transported to the lower 
channel will be a measure of the dynamics of vascular permeability based on its 
inflammatory response to thrombin treatment.  
Endothelial barrier integrity was determined by real-time measurement of tracer 
molecule transport to the lower abluminal channel from the upper luminal channel, 
wher the endothelial cells were grown to confluence on the semi-permeable 
membrane separating the two channels. FITC sodium salt and FITC-dextran 4kD 
were used as low and high molecular weight tracer molecules respectively and 
they were analyzed photometrically. Figure 29  A and B shows the permeability 
curve for FITC sodium salt and FITC-dextran respectively, along with the control 
case where the cells were not treated with thrombin. The data sample was 
collected from the lower abluminal channel every 10 min. Tracer molecule 
concentration was quantified by comparing the fluorescence intensity of collected 
data samples to a concentration calibration curve. It is observed that for both tracer 
molecules, the concentration in lower channel starts to increase acutely within 10 
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min of thrombin treatment and reaches the max value (0.09 mg/ml for FITC sodium 
salt and 0.34 mg/ml for FITC-Dextran 4kDa) within 20-30 min. This means the 
permeability or gap formation of the endothelial cell monolayer initializes rapidly 
under flow and reaches its maximum within 20-30 minutes. There is an increase 
of around 3.5 times in permeability for both tracer molecules by then and this is a 
direct measure of the change in endothelial cell-cell gap formation. Then a fall in 
abluminal concentration of tracer molecule is observed which plateaus to a 
minimum value at about 60-70 min. This signifies the decrease in endothelial cell 
permeability due to the reduction in intercellular gaps as a result of barrier recovery 
by the endothelial cells after the acute increase in permeability. FITC sodium salt 
and FITC-dextran were included in flow media at different concentrations in the 
luminal channel for ease of photometrical detection and analysis. Vascular 
permeability dynamics of similar nature in BAOECs by thrombin have been 
elucidated in previous studies [208-210, 212-213]. 
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Figure 29: Permeability of the tracer molecule through the endothelial cell layer in 
the biomimetic device. (A) Permeability of FITC dye through the endothelial cell 
layer when treated with thrombin at 1 U/ml compared to control case. (B) 
Permeability of FITC dextran 4kDa through the endothelial cell layer when treated 
with thrombin at 1 U/ml compared to control case. (C) Normalized comparison of 
FITC dye and FITC dextran 4 kDa permeability on the endothelial cell monolayer 
when treated with thrombin at 1 U/ml. FITC dye with a lower molecular weight has 
higher permeability compared to FITC dextran 4 kDa. Asterisks indicate values 
significantly different from control values (p < 0.05). 
Figure 29 C compares the concentration of the tracer molecules in the abluminal 
channel to their luminal concentration. For this, the concentration of tracer 
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molecule in the abluminal channel is divided by the respective luminal 
concentration and compared versus the thrombin treatment time. This normalizes 
the effect of doing the tests at different luminal concentrations for the two tracer 
molecules to an extent, and gives an idea on how the size of the tracer molecule 
affects permeability. It is found that the permeability of tracer molecule across the 
endothelial cells decreased with increasing molecular weight. The lower molecular 
weight FITC sodium salt diffused more through the intercellular gaps than the 
higher molecular weight FITC-dextran 4kD. Similar results have been previously 
observed in studies using tracer molecules of different size [214-218]. A reduction 
in diffusivity was observed with an increase in molecular weight of the tracer 
molecule. 
7.3.3 Characterizing vascular permeability using transwell inserts 
We compared the permeability data generated on the biomimetic platform to that 
produced using traditional transwell inserts. On transwell inserts we maintained a 
static culture of endothelial cells and treated with thrombin on reaching confluence. 
As explained in the methods section, we collect all the tracer molecules in the 
abluminal side in the blood vessel model by flushing 6 µl of buffer solution through 
the lower channel every 10 min. Whereas in the transwell study only half of the 
total tracer molecules that permeated to the abluminal side gets collected. So the 
following reading would have leftover tracer molecules from the previous time 
point. We normalized this effect for the transwell data by mathematically 
subtracting the possible amount of tracer molecule leftover from the previous time 
point for all data points. As shown in Figure 30 A, thrombin significantly increased 
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the permeability of endothelial cell monolayer within 10 min, which reached a 
maximum by about 20-30 min. After this we observed a fall in tracer molecule 
concentration which signifies a decrease in endothelial permeability. The 
permeability is comparable to control case within about 80 min of thrombin 
treatment.  
The dynamics of vessel permeability observed in the biomimetic blood vessel 
model and the traditional transwell system are similar. The recovery of endothelial 
barrier function was a steady and relatively slower process in the static transwell 
insert studies (about 80 min to plateau) compared to the flow integrated 
microfluidic blood vessel platform. The permeability was comparable to basal 
levels after about 80 min of thrombin treatment, compared to that achieved within 
60-70 min in the biomimetic platform (Figure 30 B). We further examined the F-
actin remodeling under thrombin treatment on endothelial cells in these two 
different platforms, to compare the transient nature of stress fiber alignment related 
to barrier integrity recovery.   
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Figure 30: Permeability of tracer molecule through the endothelial cell layer in the 
transwell insert study. (A) Permeability of FITC dextran 4kDa through the 
endothelial cell layer when treated with thrombin at 1 U/ml compared to control 
case. (B) Normalized comparison of FITC dextran 4 kDa permeability on the 
endothelial cell monolayer in the biomimetic device and transwell insert case on 
thrombin treatment. Endothelial cell monolayer in the biomimetic device recovers 
its barrier integrity within about 60 min compared to about 80 min in the transwell 
insert case. Asterisks indicate values significantly different from control values (p 
< 0.05). 
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7.3.4 F-actin cytoskeletal remodeling 
Thrombin treatment of endothelial cells leads to F-actin cytoskeletal filament 
formation and rearrangement. Thrombin induces myosin light chain 
phosphorylation and subsequent activation of acto-myosin based contractile 
systems. This leads to isometric tension development in the cell and thus 
endothelial cell retraction and increase in vessel permeability [219-222]. After 
demonstrating the kinetics of endothelial cell monolayer permeability through 
tracer molecule transport in static (endothelial cells cultured on transwell inserts) 
versus flow case (endothelial cells cultured in the biomimetic blood vessel model), 
confocal microscopy and immunofluorescence staining was used to examine the 
changes in F-actin stress fiber arrangement after thrombin treatment (1 U/ml). 
Figure 31 and Figure 32 show z-series composite micrographs of control and 
thrombin stimulated endothelial cell monolayers for both cases respectively. The 
control case consists of a monolayer of endothelial cells with tight intercellular 
contact and predominantly peripheral cortical actin. With thrombin stimulation, F-
actin undergoes rapid and reversible redistribution and intercellular gap formation 
for both cases. 
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D E F 
Figure 31: Thrombin induces F-actin remodeling on BAOECs cultured on a cover 
slip. (A) Control case not subjected to thrombin treatment. Note the tight 
intercellular contact and predominantly peripheral cortical actin staining; (B) 20 
minutes of thrombin treatment at 1 U/ml appears to induce intercellular gap 
formation and marked increase in actin stress fiber formation. (C) 40 minutes of 
thrombin treatment at 1 U/ml increases intercellular gap formation and produces 
notable decrease in cell size possibly due to acto-myosin based cell contraction. 
(D) 60 minutes of thrombin treatment at 1 U/ml seems to reduce intercellular gaps. 
(E) 80 minutes of thrombin treatment at 1 U/ml has significantly reduced 
intercellular gaps and there is significant decrease in F-actin stress fiber presence. 
(F) 100 minutes of thrombin treatment at 1 U/ml produce cell characteristics 
comparable to control case. (Scale bar: 25 µm) 
C 
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(B) 20 min 
(C) 40 min 
(D) 60 min 
(A) Control 
Figure 32: BAOECs cultured in the microfluidic biomimetic device are treated with thrombin along 
with flow which induces F-actin remodeling. (B) 20 minutes of thrombin treatment at 1 U/ml produce 
regions without F-actin stress fibers between cells which signify inter-cellular gap formation. (C) 
These gaps tends to reduce and bridge by increased cortical actin presence towards the cell 
periphery after 40 minutes of thrombin treatment. (D) There is steady presence of F-actin filaments 
on the cell monolayer after 60 minutes of thrombin treatment, signifying the decrease in inter-cellular 
gaps. (Scale bar: 25 µm) 
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For the static case where the cells were cultured on cover slips, detailed orientation 
of F-actin fibers and cell-cell gap formation were visible (Figure 31). After 20 min 
of thrombin treatment the actin had reorganized into prominent stress fibers 
aligned parallel to each other and to the long axis of the cell. Compared to the 
control case, the cells had retracted from one another and exhibit small gaps 
between adjacent cells while retaining their polygonal morphology. The endothelial 
cells still remained attached to one another and in many areas the stress fibers 
appeared to be contiguous between adjacent cells. 40 min of thrombin treatment 
increased intercellular gaps and produced notable decrease in cell size possibly 
due to acto-myosin based cell contraction. There was a reduction in intercellular 
gaps and a reversal in thrombin based inflammatory response by 60 min of 
treatment. 80 minutes of thrombin treatment produced cell monolayers with 
significantly reduced intercellular gaps and there was also a significant decrease 
in the presence of F-actin stress fiber in the cell cytoplasm. The 100 min case had 
cell characteristics comparable to that of control (no thrombin treatment) case.  
The biomimetic blood vessel platform being thin enough allowed imaging of the 
endothelial cells at 60x magnification using an oil immersion objective. But the 
presence of multiple layers (glass, PDMS, membrane) of different refractive 
indices between the cell and the objective resulted in images that were 
compromised on details. Stress fiber presence and orientation were not well 
described in these images, but details on cell-cell gap formation were available 
(Figure 32). 20 min of thrombin treatment on endothelial cells under flow resulted 
in intercellular regions lacking F-actin stress fibers, which signify inter-cellular gap 
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formation. After 40 min, these gaps decreased in size and frequency. The gaps 
have reduced by increased cortical actin presence towards cell periphery. Further 
thrombin treatment (60 min) lead to uniform F-actin presence throughout the cell 
monolayer with reduced intercellular gaps, which was comparable to the control 
case.  
Our results on static cover slip studies are comparable to already established 
literature. Thrombin stimulation initially causes polymerization of actin fibers in 
endothelial cells that organize into thick stress fibers and are arranged parallel to 
each other, leading to intercellular gap formation [220]. Further treatment is known 
to decrease F-actin quantity and return to the control case (no thrombin) level 
[223]. Quantifying F-actin content in thrombin activated endothelial cells has shown 
an increase in actin polymerization during the initial 30 min of thrombin treatment 
and then a reduction in total F-actin content by 60 min [220].  
7.3.5 Comparison of biomimetic model to transwell insert study 
Endothelial cells when removed from their native environment become separated 
from critical extracellular cues and can undergo phenotypic drifts. Traditional in 
vitro studies can provide an approximation of the true biology, but cannot account 
the true nature due to the lack of a holistic system [224-225]. An in vivo intact 
endothelium is exposed to multiple factors and is differentially regulated in space 
and time [224, 226]. Current in vitro platforms for studying endothelial cell biology 
and permeability have limitations in incorporating these numerous and dynamic 
factors. Our biomimetic blood vessel platform cultures endothelial cells in their 
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native flow environment and we can expose cells to multiple external cues in a 
controlled manner to understand their responses towards the heterogeneous 
environment. In vivo studies on rats and mice have found an increase in vascular 
permeability to reach its peak by around 15 min and fall back to control levels (or 
follow that trend) within 60 min of thrombin treatment [227-230]. The majority of in 
vitro studies have reported similar acute nature in the increase of vessel 
permeability by thrombin, but the dynamics of endothelial cell monolayer barrier 
recovery to reach control or baseline levels of permeability have been different. In 
vitro it usually takes longer than the average 60 min observed in vivo, an average 
of about 90-120 min [200, 208, 230-236].  
In our work we checked the permeability of endothelial cells when treated with 
thrombin in our novel biomimetic blood vessel model under flow and also in the 
traditional transwell insert static culture system. The static platform produced 
endothelial cell permeability curves comparable to other studies where the barrier 
recovery occurred by around 80-90 min. In the biomimetic blood vessel model the 
endothelial cell layer achieved barrier recovery at a similar rate, within 60-70 min. 
We examined the F-actin remodeling pattern as well to understand the gap 
formation in cells subjected to thrombin. The static case had F-actin stress fiber 
formation, disassembly, related gap formation and it's recovery on a time scale 
comparable to the tracer molecule based barrier recovery study (around 80 min). 
The endothelial cells in biomimetic blood vessel platform showed F-actin stress 
fiber based gap formation within 20 min and recovery of endothelial cell monolayer 
128 
 
barrier integrity by 60 min of thrombin treatment, supporting the tracer molecule 
permeability data.  
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7.4 Conclusion  
Endothelial cells, when removed from their native tissue environment and cultured 
on traditional in vitro platform are uncoupled from critical extracellular cues and 
have a tendency to undergo phenotypic drift. This causes changes in cell signaling 
pathways and the transcriptional control machinery making such platforms hard to 
analyze. Inflammatory responses in endothelial cells produce an increase in 
vascular permeability by formation of intercellular gaps. In this study we use an 
engineered biomimetic blood vessel microfluidic model to characterize the 
dynamic nature of increase in vascular permeability, and compare these results to 
traditional transwell insert permeability assays. The biomimetic blood vessel model 
has a monolayer of endothelial cells cultured under in vivo levels of flow. This 
endothelial monolayer was treated with thrombin, a serine protease which induces 
a rapid and reversible increase of endothelial cell monolayer permeability. 
Thrombin disrupts the endothelial barrier function of the endothelial cell monolayer 
cultured on a semi-permeable membrane, which separates the bi-layer device. 
This induces para-cellular gap formation and allows the transport of tracer 
molecules through these gaps from the upper to the lower channel. Tracer 
molecule samples are collected real time and analyzed via spectroscopy, and the 
dynamic nature of the process is observed. On the biomimetic platform and 
transwell insert studies the transient nature of increase in permeability and their 
barrier recovery was comparable. F-actin stress fiber remodelling patterns were 
also studied as reorganization of the endothelial cell cytoskeleton provided the 
structural basis for changes in vascular permeability.  
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We present here a biomimetic blood vessel model capable of culturing endothelial 
cells under flow, while being possible to trigger them spatially and temporally from 
the basal or apical side. Our biomimetic platform is an apt replacement tool to 
perform blood vessel related studies. Platform like that of ours should be able to 
bridge the void space between traditional in vitro studies and the more complicated 
in vivo studies, providing vital tools for translational research to provide therapeutic 
gain and reduce drug attrition.        
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Chapter 8 
Some general discussion and suggestions for future research 
In this thesis, microfluidics, cell biology and aspects of engineering are brought 
together to construct in vitro blood vessel platforms to answer challenging 
questions in the field of targeted drug delivery and vascular biology. In this chapter, 
we provide discussions which cut across the results, and provide some 
suggestions for future work.  
8.1 General discussions 
The first half of the thesis concentrates on building a protein coating based blood 
microvessel model to characterize specific binding of drug model particles. The 
binding density of anti-ICAM-1 coated 210 nm and 2 µm particles on ICAM-1 
modified PDMS microfluidic devices was characterized. The study employs 
various factors that influence particle distribution and binding, such as flow shear 
rate, particle size, RBCs, vessel geometry, antibody coating density on the particle, 
particle concentration and effect of asymmetric flow profiles. The results helped to 
determine the transport properties and binding of drug carriers in the 
microvasculature. Particles of the right size range provide better bioavailability and 
enhanced targeted binding, and these factors need to be considered to provide 
higher efficacy and minimal drug dosage. From this work we conclude that 2 µm 
particles have better binding efficiency based on number count and volume under 
low to medium flow shear rates. For disease conditions where a higher particle 
concentration or dosage is acceptable (drug toxicity not an issue) and higher shear 
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flows are involved, the smaller particles of the 200 nm scale would be more 
suitable. Properties like the enhanced particle margination and binding to the wall 
at high particle flow concentration observed in this work favours the use of NPs. 
Other advantages like the ability to be better retained in tissues via the enhanced 
permeability and retention effect, longer circulation period and better targeting 
ability are also in favour of NPs. When designing targeted vascular drug carriers 
various parameters have to be considered like the disease condition, permissible 
drug toxicity based particle concentration, reticuloendothelial system evading 
properties etc. Inspired by this work we developed the customizable biomimetic 
microfluidic blood vessel platform based on culturing endothelial cells under flow. 
This model is capable of mimicking specific blood vasculature conditions based on 
disease state and physiological spot of origin. 
The biomimetic blood vessel model developed and explained in the second half of 
the thesis is a tool with unprecedented ability to investigate the microenvironment 
of endothelial cells. The simplicity of traditional in vitro models, which usually 
consist of a single cell type, makes them robust and suitable for high throughput 
research, but unfortunately provides only little biological relevance to the complex 
biological tissues of the real system. Furthermore, the culture conditions do not 
closely mimic the in vivo microenvironment due to the absence of the fluid flow and 
shear stresses [237]. Also, these cultures are less suited to provide a dynamically 
controlled flow of cell nutrients and stimuli and, additionally, the accumulation of 
waste leads to a pH drift in a static culture. Other drawbacks of the classical cell 
culture systems are the long growth times needed for cells to differentiate into 
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functional cells and the dependence on external signal detection systems that 
require manual withdrawing and manipulation of samples. The microfluidic chip we 
developed can mimic a close to native environment for endothelial cells by 
facilitating in vivo levels of flow and biomolecule supply, along with features that 
allow real-time studies. The endothelial monolayer can be accessed from their 
apical and basal side, allowing simulation of physiologic conditions was endothelial 
cells are triggered from blood vessel lumen side or tissue side or both. We 
characterized BAOEC culture under physiological levels of flow and analyzed their 
F-actin organization pattern. We utilized this platform to understand endothelial 
microenvironment responses to inflammatory triggering. Localized TNF-α 
treatment was performed on the BAOECs from the basal side of the cell and ICAM-
1 upregulation in the upstream, TNF-α treated and downstream section of the 
channels were analyzed. Anti-ICAM-1 coated fluorescent imaging probes were 
used to characterize the upregulation of surface-ICAM-1 on endothelial cells. 
Particle binding per cell data was obtained using 210 nm particles and 1 µm 
particles. By analyzing the particle binding along the length of the channel we 
characterized the nature of ICAM-1 expression for BAOECs along the channel 
length. We also outlined the nature of TNF-α based actin depolymerization and 
rearrangement along channel length. This platform also enabled the real-time 
study of increase in surface-ICAM-1 expression on endothelial cells by studying 
the amount of particle binding over time while TNF-α treatment was performed. It 
was of interest to note that ICAM-1 expression dynamics were different for cells 
cultured under flow from those in a static culture. The same platform was modified 
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to suit an assay to understand the dynamics of change in vascular permeability. 
Endothelial cells exhibit a loss of vascular barrier integrity as part of its response 
to inflammatory stimuli. Endothelial cell monolayers cultured under flow in our 
device were treated with thrombin, an acute inflammatory mediator. The dynamics 
of vascular permeability were understood by studying the extent of tracer molecule 
diffusion through the endothelial cell monolayer to the lower channel. The work 
was compared to traditional transwell insert study and the cells cultured under flow 
recovered their barrier integrity at a faster rate compared to the static case. These 
studies highlight the versatile nature and functionality of the microfluidic biomimetic 
blood vessel platform developed. This allowed studying detailed physiological 
events related to blood vessels, and in consequence understanding the influence 
of specific biomolecules on a specific function as well as on the healthy/diseased 
state modulation. 
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8.2 Future research 
8.2.1 Co-culture of endothelial cells and SMCs  
Endothelial cell-SMC interactions play a synergistic role in endothelial cell 
development, cell proliferation and differentiation, their response to growth factors, 
mechano-chemical coupling, cell motility and directional control [238-240]. 
Platforms where these two cell types are grown on the opposite sides of membrane 
have already been established [241-242] and applied to study the influence of 
SMCs in the effect of shear stress on endothelial biology [239], and SMC influence 
on the patterns of leukocyte adhesion to the endothelial cell [240]. We have done 
some initial scouting on how to facilitate SMC co-culture along with endothelial 
cells on our biomimetic blood vessel model to take it a step closer to mimicking in 
vivo niche.   
The dimensions and shape of our established biomimetic blood vessel platform 
can be tuned to fit the co-culture of SMCs along with endothelial cells. The lower 
channel will be wider to increase the co-culture area and both channels will have 
the ability to be accessed separately. The upper and lower channel along with the 
membrane will be coated with 50 µg/ml fibronectin solution overnight at 37oC. 
BAOECs will be seeded onto the semi-permeable membrane in the upper channel 
followed by BAOSMCs cells seeding onto the semi-permeable membrane in the 
lower channel. The device will be placed in the incubator under standard culture 
conditions (37oC and 5% CO2) for 4 hrs after both cases of cell seeding to allow 
cell attachment and spreading on the membrane. Media will be frequently changed 
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in both the channels. We performed a proof-of-concept trial of this protocol and the 
cells were cultured for a day. Both the BAOECs and BAOSMCs were stained with 
Calcein AM (live cell stain) to evaluate their viability. Figure 33 shows micrographs 
of confluent layers of BAOECs and BAOSMCs growing in the upper and lower 
channel respectively. Further work on this platform can be conducted by subjecting 
the co-culture cell system to relevant FSS from the endothelial cell side and 
performing further characterizations. 
 
 
8.2.2 Leukocyte recruitment and trans-migration studies 
Our platform can also be tuned to perform leukocyte recruitment and trans-
migration studies on an endothelial cell layer under inflammatory conditions. 
Recruitment of leukocytes from blood to tissues is a multi-step process playing a 
E 
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Endothelial cell 
Figure 33: Image of a microfluidic platform devised to co-culture endothelial cells 
and SMCs on the opposite sides of a membrane. (A) Culture of endothelial cells 
and SMCs on the opposite sides of a porous membrane;          Brightfield 
micrograph of the upper channel (B) and of the lower channel (C); Calcein AM 
stained (D) BAOECs in upper channel and (E) BAOSMCs in lower channel.  
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major role in the activation of inflammatory responses. Tethering and rolling of 
leukocytes along the vessel wall, followed by arrest and transmigration through the 
endothelium result from chemo-attractant dependent signals. Shear forces exerted 
by the blood flow on leukocytes induce rolling via selectin-mediated interactions 
with endothelial cells and increase the probability that leukocytes will engage their 
chemokine receptors, facilitating integrin activation and consequent arrest. Flow 
based shear forces generate mechanical stimuli along with biochemical signals in 
the modulation of leukocyte-endothelial cell interactions [243]. The limitation of the 
static environment can be overcome with our custom built blood vessel model 
mimicking the in vivo conditions. Our device can create an in vitro biomimetic 
environment where the multi-step transmigration process can be imaged and 
quantified under mechanical and biochemical controlled conditions, including fluid 
dynamic settings, channel design, materials and surface coatings.  By using an 
appropriate semi-permeable membrane (with a pore size that will allow leukocyte 
migration), we can study the dynamics and kinetics of the process. The results 
should be able to throw light at details of the process that are still elusive.  
8.2.3 Modeling tumor environment  
During tumor growth, some unique pathophysiological characteristics that are not 
observed in normal tissues or organs are present, such as extensive angiogenesis 
and hence hypervasculature, defective vascular architecture, impaired lymphatic 
drainage/recovery system, and greatly increased production of a number of 
permeability mediators. This leads to higher pressure inside tumors. While the 
interstitial fluid pressure (IFP) in normal tissues is actively controlled and remains 
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close to atmospheric levels, IFP in most human tumors is highly elevated [159]. 
Other causes of IFP include increased resistance to interstitial fluid flow and 
impaired lymphatic drainage [244]. As a result, transporting drug molecules into 
solid tumors can be a challenge. Cancer also remains the leading cause of death 
mainly due to tumor invasion and metastasis [245]. Studies on tumor invasion have 
not yet brought to light the details of the invasion cascades [246-247]. The entry of 
tumor cells into blood vessels is an important route for penetrating into the 
circulatory system and subsequently metastasizing to another organ through blood 
vessel walls [248]. Reproducing a tumor microenvironment consisting of blood 
vessels and tumor cells for modeling tumor invasion in vitro can provide answers 
to above mentioned maladies, but constructing such a system is particularly 
challenging. By tuning the right parameters we can model such a tumor 
microenvironment by growing 3D tumor blocks in hydrogel in the lower channel of 
our blood vessel model. This allows the study of blood vessel-3D tumor 
microenvironment interaction. The results and answers that could be generated on 
such a controlled tumor environment-blood vessel model would be relevant from 
a physiology and therapeutic perspective. 
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